# Chapter 128: Mild Neurocognitive Disorder

# The Biological and Neurological Basis of Mild Neurocognitive Disorder

## Introduction

Mild Neurocognitive Disorder (MND), a diagnostic entity introduced in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), represents a crucial stage in the continuum of cognitive aging (Presečki et al., 2014). This syndrome is characterized by a modest, yet noticeable, decline in cognitive function from a previous level of performance in one or more cognitive domains, such as complex attention, executive function, learning and memory, language, perceptual-motor skills, or social cognition (Presečki et al., 2014; Rucci & Feinstein, 2014). This decline is substantiated by concern from the individual, a knowledgeable informant, or the clinician, and is documented by objective neuropsychological testing or another quantified clinical assessment (Presečki et al., 2014; Martínez Cortés, 2013). A key feature distinguishing MND from Major Neurocognitive Disorder (dementia) is that the cognitive deficits do not interfere with the capacity for independence in everyday activities, although greater effort, compensatory strategies, or accommodation may be required (Presečki et al., 2014; Andrès, 2021).

The concept of MND is closely related to the widely studied clinical construct of Mild Cognitive Impairment (MCI) (Ibrahim & Amar, 2007; Petersen, 2004). MCI is often conceptualized as a transitional state between the cognitive changes of normal aging and the more pronounced deficits of dementia (Ibrahim & Amar, 2007; Petersen, 2004; Janelidze & Botchorishvili, 2018). While some gradual mental decline is a feature of normal aging, such as reduced speed of mental processing, MCI represents a decline that is greater than expected for an individual's age and educational level (Andrès, 2021; Gounard & Hulicka, 1977; Morris & McManus, 1991). The prevalence of MCI is substantial, affecting approximately 12-18% of individuals aged 60 or older, and it is recognized as a significant risk factor for progression to dementia, particularly Alzheimer's disease (AD) (Dana, 2021; Panza et al., 2006). However, the trajectory is not inevitable; some individuals with MND or MCI remain stable for many years, while others may even revert to a cognitively normal state (Munro, 2018; Petersen, 2004).

The biological underpinnings of MND are profoundly heterogeneous, reflecting a wide array of potential etiologies (Presečki et al., 2014). It is not a single disease but a clinical syndrome that can be the initial manifestation of various neurodegenerative processes (e.g., Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration), cerebrovascular disease, traumatic brain injury, substance or medication use, or other systemic medical conditions (Presečki et al., 2014; Drossel, 2020; Hulse et al., 2005). This etiological diversity underscores the complexity of its neurobiology. Understanding the biological and neurological mechanisms that drive the cognitive decline in MND is paramount for developing effective diagnostic biomarkers, predicting progression, and designing targeted interventions to slow or prevent the transition to dementia (Bullock, 2005). This chapter will provide a comprehensive overview of the current understanding of these mechanisms, drawing upon evidence from neurochemical, genetic, cellular, and neuroimaging studies. We will explore the roles of neurotransmitter systems, neural circuits, genetic predispositions, synaptic dysfunction, and structural brain changes in the pathophysiology of this critical and increasingly prevalent condition.

## Neurobiological Systems

The cognitive deficits characteristic of Mild Neurocognitive Disorder arise from dysfunction across multiple integrated neurobiological systems. While no single mechanism can account for the heterogeneity of the syndrome, dysregulation within key neurotransmitter systems, alterations in neural circuits, and widespread cellular pathologies are consistently implicated. These changes disrupt the delicate balance of neuronal communication, synaptic plasticity, and network integrity required for efficient cognitive processing (Pinelli, 2008). The specific systems affected often correspond to the clinical subtype of MND and its likely underlying etiology, such as Alzheimer's disease, vascular disease, or frontotemporal lobar degeneration (Presečki et al., 2014; Drossel, 2020).

### Neurotransmitter Systems and Neuropharmacology

The complex processes of learning, memory, attention, and executive function are modulated by a precise interplay of neurotransmitter systems (Sunderland et al., 1997; Cools et al., 2011). Disruptions in these systems are central to the pathophysiology of cognitive decline.

**The Cholinergic System:** The central cholinergic system is fundamentally involved in memory and learning processes (Sunderland et al., 1997; Schneider & Abou‐Saleh, 2002). A significant decline in cholinergic transmission is a well-established hallmark of Alzheimer's disease (AD), a leading cause of MND and its most common progression (Galasko, 2019; Vally & Kathrada, 2019). The neuropathology of AD involves neuronal loss in cholinergic nuclei, leading to reduced acetylcholine levels in critical brain regions like the hippocampus and cortex (Love & Geldmacher, 2018). This deficit directly contributes to the episodic memory impairment that is the cardinal feature of amnestic MCI, the subtype most often considered a prodromal stage of AD (Petersen, 2004; Dickerson & Sperling, 2007). The clinical relevance of this system is underscored by the therapeutic strategy of using acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine), which aim to boost synaptic acetylcholine levels and provide modest symptomatic benefit in AD (Rucci & Feinstein, 2014; Vally & Kathrada, 2019). Furthermore, the cognitive side effects of many medications, particularly those with anticholinergic properties, can induce or exacerbate cognitive impairment, mimicking or worsening MND symptoms, a phenomenon known as anticholinergic burden (Kojima & Akishita, 2016; Stoner et al., 2020). Delirium, an acute confusional state that shares features with and is a risk factor for MND, is also strongly linked to cholinergic deficiency (Francis, 1997; Mukadam et al., 2007).

**The Dopaminergic System:** Dopamine is crucial for executive functions, motivation, and reward processing, functions primarily mediated by fronto-striatal circuits (Ereshefsky et al., 1990; Cools et al., 2011). Dysfunction in this system is implicated in the non-amnestic subtypes of MND, particularly those characterized by apathy, executive dysfunction, and psychomotor slowing (Martínez‐Castrillo et al., 2011). For instance, the apathy and motivational deficits seen in some individuals with MND are consistent with the known role of the mesolimbic dopamine system in reward and goal-directed behavior (Koob, 2013; Scuvée‐Moreau, 2013). Degeneration of dopaminergic neurons in the substantia nigra is the pathological basis of Parkinson's disease (PD), a condition frequently associated with cognitive impairment and dementia (Sesar et al., 2011; Rajput et al., 1989). Cognitive deficits can appear early in PD, often involving executive dysfunction, which is linked to the depletion of dopamine in the caudate nucleus (Lévy & Pillon, 2006). Pharmacological agents that modulate dopamine, such as levodopa, can have variable and sometimes paradoxical effects on cognition in PD patients (Leiva Santana & Álvarez Saúco, 2006; Cools et al., 2011). Furthermore, the abuse of stimulant drugs like cocaine and amphetamines, which act on the dopamine system, is associated with both acute and chronic cognitive deficits (Cadet & Bolla, 1996; Saberi, 2020).

**Serotonergic and Noradrenergic Systems:** These monoamine systems are broadly involved in mood, arousal, attention, and cognitive regulation (Morilak, 2007; Yan et al., 2011). Dysregulation of serotonin and norepinephrine is a cornerstone of the neurobiology of major depressive disorder (MDD) (Greden, 2003; Schneider & Abou‐Saleh, 2002). Given that late-life depression is a significant risk factor for, and often co-occurs with, MND and subsequent dementia, the involvement of these systems is highly relevant (Wilkins, 2008; Rahma, 2021; Kitching, 2015). Depression itself is associated with substantial cognitive impairment, particularly in executive function, processing speed, and memory (Pan et al., 2018; Knight et al., 2019), and these deficits can persist even after mood symptoms remit (Boeker et al., 2012). Antidepressants that target these systems, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), can sometimes improve cognitive function, possibly secondary to mood improvement but also potentially through direct pro-cognitive effects (Glass, 1981; Knight et al., 2019; Oleychik et al., 2020). Conversely, withdrawal from these medications can lead to a discontinuation syndrome that includes cognitive symptoms like difficulty concentrating (Schatzberg et al., 1997; Chouinard & Chouinard, 2015).

**The Glutamatergic System:** Glutamate is the primary excitatory neurotransmitter in the central nervous system and is essential for synaptic plasticity, learning, and memory (Wolf, 2002). However, excessive glutamatergic activity can lead to excitotoxicity, a process of neuronal damage and death implicated in a wide range of neurological disorders, including ischemic stroke, traumatic brain injury, and neurodegenerative diseases (Yang et al., 2021; Volpe, 1997). This pathological cascade is considered a key mechanism underlying the neuronal loss seen in conditions that present with MND (Kalimo & Smith, 1986). The N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor, is critically involved in both long-term potentiation (a cellular basis for memory) and excitotoxicity (Trujillo, 2012). The therapeutic agent memantine, used in moderate to severe AD, acts as a non-competitive NMDA receptor antagonist, aiming to protect against excitotoxicity while preserving physiological receptor function (Vally & Kathrada, 2019; Jones et al., 2016). The involvement of glutamate is also central to the neurobiology of addiction, where drug-induced alterations in glutamatergic plasticity in circuits like the nucleus accumbens are thought to drive compulsive drug-seeking and relapse (Wolf, 2002; Quintero Garzola, 2013).

## Genetic and Molecular Basis

The development of Mild Neurocognitive Disorder is influenced by a complex interplay of genetic predispositions and environmental factors (Ivlieva, 2011). While MND itself is a clinical syndrome rather than a specific genetic disease, its underlying etiologies often have a significant genetic component. Research into the heritability of neurodegenerative diseases, psychiatric disorders, and substance use disorders provides critical insights into the molecular pathways that confer vulnerability to cognitive decline.

### Genetic Factors and Heritability

The risk for many conditions that manifest as MND is influenced by genetics. For instance, Alzheimer's disease (AD), the most common cause of amnestic MCI, has a strong heritable component (Sadowski, 2010). While rare, early-onset familial AD is caused by autosomal dominant mutations in specific genes, the more common late-onset form is polygenic, with the Apolipoprotein E (APOE) gene being the most significant known genetic risk factor (Willroth et al., 2022). Similarly, a substantial proportion of frontotemporal dementia (FTD) cases are familial, with mutations identified in several genes (Kerchner & Rosenbloom, 2014; Sander, 2015). The presence of a causative genetic mutation is considered sufficient evidence for a "probable" diagnosis of FTD-related MND (Kerchner & Rosenbloom, 2014).

Beyond specific dementia-related genes, genetic factors are implicated in a wide range of conditions associated with cognitive impairment. For example, genetic predisposition is a known factor in the development of substance use disorders, which can lead to significant and sometimes lasting cognitive deficits (Winters & Ingwalson, 2022; Blum & Trachtenberg, 1988). Studies on alcoholism suggest that deficiencies in neurotransmitter systems, which can be genetically determined, may underlie the craving for alcohol and contribute to its neurotoxic effects (Blum & Trachtenberg, 1988). Similarly, psychiatric disorders like major depression and schizophrenia, both associated with cognitive dysfunction, have established heritability (Papmeyer et al., 2015; Chen & Murray, 2004). The presence of a family history of affective disorder is a significant correlate for chronic primary depression (Akiskal, 1982). Furthermore, rare genetic neurodevelopmental disorders, such as *SCN3A*-related neurodevelopmental disorder or *FBXL4*-related encephalomyopathic mitochondrial DNA depletion syndrome, consistently present with severe cognitive impairment, illustrating the profound impact of single-gene defects on brain function (Helbig & Goldberg, 2021; Almannai et al., 2017). Even in epilepsies, certain syndromes with a strong genetic basis, such as Dravet syndrome, are associated with a characteristic cognitive decline that begins shortly after seizure onset (Guerrini & Falchi, 2011). The polygenic nature of many of these conditions suggests that vulnerability arises from the cumulative effect of many genes, each with a small impact, interacting with environmental and lifestyle factors (Ivlieva, 2011).

### Molecular Mechanisms

At the molecular level, the pathophysiology of MND involves the disruption of numerous critical cellular processes, leading to synaptic dysfunction, neuronal injury, and ultimately, cell death (Agid & Blin, 2007).

**Protein Misfolding and Aggregation:** A central molecular theme in many neurodegenerative diseases underlying MND is the misfolding and aggregation of specific proteins (Grasso et al., 2011). In AD, this involves the extracellular deposition of beta-amyloid (Aβ) peptides into senile plaques and the intracellular accumulation of hyperphosphorylated tau protein into neurofibrillary tangles (NFTs) (Kozaki, 2018; Vally & Kathrada, 2019). The accumulation of Aβ is thought to be an early event in the disease cascade, potentially beginning decades before clinical symptoms emerge, a period sometimes referred to as the "brain AD stage" (Sadowski, 2010; Jack et al., 2010). NFT pathology, in contrast, correlates more closely with the severity of clinical symptoms and neuronal loss (Kozaki, 2018). In dementia with Lewy bodies (DLB) and Parkinson's disease, the key pathological protein is α-synuclein, which aggregates to form Lewy bodies and Lewy neurites (Bencze et al., 2017). In a subset of FTD, aggregated tau is also the primary pathology, while in others, proteins like TDP-43 or FUS are involved (Kerchner & Rosenbloom, 2014). These protein aggregates are believed to be neurotoxic, disrupting cellular functions, impairing axonal transport, and triggering inflammatory responses (Grasso et al., 2011).

**Oxidative Stress and Mitochondrial Dysfunction:** The brain has high energy demands, making it particularly vulnerable to metabolic disturbances and oxidative stress (Perez‐Polo, 1991). Chronic alcohol consumption, for example, induces significant oxidative stress, which is a key mechanism contributing to alcohol-related brain damage and cognitive dysfunction (Chopra & Tiwari, 2012; Matuszewska et al., 2025). Mitochondrial dysfunction is another critical factor, as it impairs cellular energy production and increases the generation of reactive oxygen species (ROS), further exacerbating oxidative stress (Chopra & Tiwari, 2012). This pathway is implicated in both neurodegenerative diseases and toxic encephalopathies (Perez‐Polo, 1991; Kapczinski, 2015). Some medications are known to cause neurotoxicity by interfering with mitochondrial function, leading to conditions like mitochondrial optic neuropathies (Wang & Sadun, 2013).

**Neuroinflammation:** There is growing evidence that neuroinflammatory processes play a crucial role in the pathogenesis of cognitive decline (Kapczinski, 2015; Yirmiya et al., 2015). Chronic activation of microglia, the brain's resident immune cells, can lead to the release of pro-inflammatory cytokines and other neurotoxic molecules, contributing to neuronal damage and synaptic loss (Yirmiya et al., 2015; Lasić et al., 2015). This inflammatory cascade is observed in AD, where microglia are found surrounding amyloid plaques, and is also a key feature of sepsis-associated encephalopathy, a condition that can lead to long-term cognitive impairment (Magalhaes et al., 2014; Rengel et al., 2019). The interaction between stress, glucocorticoids, and neuroinflammation is also considered a dangerous liaison for vulnerable brain structures like the hippocampus (Komoltsev & Gulyaeva, 2022).

**Apoptosis and Regulated Cell Death:** Neuronal loss in neurodegenerative diseases and following acute brain insults like ischemia is not solely a passive process of necrosis but often involves regulated cell death pathways, such as apoptosis (programmed cell death) (Yang et al., 2021; Scaravilli, 1998). These pathways are activated by various triggers, including protein aggregates, oxidative stress, inflammation, and excitotoxicity (Yang et al., 2021). The activation of these molecular cascades leads to the systematic dismantling of the neuron, a process that contributes to the progressive brain atrophy seen in diseases underlying MND (Agid & Blin, 2007; Grasso et al., 2011). Understanding these specific molecular pathways is crucial for the development of neuroprotective therapies aimed at halting the degenerative process at an early stage (Jain, 2019; Lieberman et al., 2007).

## Brain Structure and Function

Mild Neurocognitive Disorder is fundamentally a reflection of altered brain structure and function. Advances in neuroimaging and electrophysiology have provided invaluable windows into the living brain, allowing researchers and clinicians to identify the neural correlates of cognitive decline. These techniques reveal patterns of atrophy, altered metabolism, and disrupted connectivity that often precede the onset of dementia and can help differentiate between the various underlying etiologies of MND (John et al., 1988).

### Neuroimaging Findings

**Structural Neuroimaging:** Magnetic Resonance Imaging (MRI) is a cornerstone in the evaluation of cognitive impairment, primarily to exclude other pathologies but also to identify patterns of atrophy suggestive of specific neurodegenerative diseases (Presečki et al., 2014). In amnestic MCI, which frequently represents prodromal Alzheimer's disease (AD), the most characteristic finding is atrophy of medial temporal lobe structures, particularly the hippocampus and entorhinal cortex (Dickerson & Sperling, 2007; Sadowski, 2010). The volume of these structures is often correlated with the severity of episodic memory impairment (Bainbridge et al., 2019). Over time, this atrophy typically spreads to involve temporal and parietal association cortices (Lléo & Blesa, 2011). In contrast, non-amnestic presentations of MND may be associated with different patterns. For instance, the behavioral and language variants of frontotemporal dementia (FTD) are associated with disproportionate atrophy in the frontal and/or temporal lobes, respectively (Kerchner & Rosenbloom, 2014; Sander, 2015). Vascular cognitive impairment, another common cause of MND, is associated with evidence of cerebrovascular disease on MRI, such as lacunar infarcts, white matter hyperintensities, or evidence of a strategic infarct in a cognitively relevant brain region (Boytsov & Samorodskaya, 2022; Panza et al., 2009). The presence of these neuroimaging findings can increase the diagnostic certainty from "possible" to "probable" for specific etiological subtypes of MND (Kerchner & Rosenbloom, 2014).

**Functional Neuroimaging:** Functional imaging techniques, such as Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), provide information about brain metabolism and perfusion. In individuals with amnestic MCI who progress to AD, a typical finding on FDG-PET (which measures glucose metabolism) is hypometabolism in the posterior cingulate/precuneus and temporoparietal regions (Dickerson & Sperling, 2007; Kozaki, 2018). This pattern can help differentiate AD from other dementias like FTD, which typically shows frontal and/or anterior temporal hypometabolism (Kerchner & Rosenbloom, 2014). Amyloid PET imaging, which visualizes the burden of beta-amyloid plaques in the brain, is another important tool. A positive amyloid scan in a person with MCI significantly increases the likelihood that the cognitive impairment is due to underlying AD pathology (Sadowski, 2010). These functional changes often appear before significant structural atrophy is evident, highlighting their potential as early diagnostic markers (Jack et al., 2010). Functional MRI (fMRI) studies have also revealed alterations in brain activity, suggesting that individuals with MCI may show either reduced activation in key memory areas or, in some cases, compensatory hyperactivation as the brain attempts to cope with the underlying pathology (Smith et al., 2013).

### Neural Circuits and Functional Connectivity

Cognition is not the product of isolated brain regions but emerges from the coordinated activity of large-scale neural networks (Pinelli, 2008). MND is increasingly understood as a "disconnection syndrome," where the primary pathology disrupts the functional integrity of these networks (Cadet & Bolla, 1996).

**The Default Mode Network (DMN):** The DMN is a network of brain regions, including the posterior cingulate/precuneus, medial prefrontal cortex, and medial temporal lobes, that is typically active during rest and internally focused thought. This network is heavily implicated in episodic and autobiographical memory. In AD and amnestic MCI, there is consistent evidence of reduced functional connectivity within the DMN (Stamoulis & Chang, 2011). This disruption is thought to be a direct consequence of AD pathology accumulating in the network's key nodes and is closely linked to the memory deficits that characterize the condition.

**Fronto-parietal and Executive Control Networks:** Executive functions, such as planning, working memory, and cognitive flexibility, rely on networks involving the dorsolateral prefrontal cortex and posterior parietal regions (Sun, 2018). Disruption of these fronto-parietal networks is a common feature in various forms of MND, not limited to FTD (Tedeschi et al., 2015). For example, cognitive deficits in vascular cognitive impairment are often characterized by executive dysfunction, reflecting damage to subcortical-frontal circuits from small vessel disease (Novikova & Захаров, 2021). Similarly, conditions like chronic alcoholism and substance abuse lead to prominent executive deficits linked to dysfunction in these frontal systems (Bernardin et al., 2014; Báusela Herreras & Martínez Gutiérrez, 2008).

**Diaschisis:** An important concept in understanding widespread brain dysfunction following a focal lesion is diaschisis. This refers to the depression of function in brain regions that are anatomically connected to, but remote from, the site of an acute injury, such as a stroke (Meyer et al., 1993; Sánchez Chávez, 1999). This phenomenon highlights how a localized insult can have far-reaching consequences on distributed neural networks, contributing to a global picture of cognitive impairment that may be disproportionate to the size of the initial lesion.

### Electrophysiology

Electroencephalography (EEG) provides a measure of the brain's electrical activity and is a sensitive tool for detecting diffuse cerebral dysfunction (Kügler et al., 1977). In many conditions associated with cognitive impairment, such as metabolic or toxic encephalopathies, a common finding is a generalized slowing of the EEG background rhythm (Rayi & Mandalaneni, 2021; Smith, 2005). While non-specific, this finding indicates a widespread disturbance of cortical function (Kügler et al., 1977). In some individuals with MND, particularly those with an underlying epileptic process, the EEG may show interictal epileptiform discharges (IEDs). These discharges, even when not associated with overt seizures, can cause transient cognitive impairment (TCI) and may contribute to more chronic cognitive deficits over time (Jennekens‐Schinkel & Meekes, 2018; Sugimoto et al., 2013). Non-convulsive status epilepticus (NCSE), a state of continuous seizure activity without major motor signs, can present as an acute confusional state or a more insidious cognitive decline, mimicking a rapidly progressing dementia, and is a critical diagnosis to make as it is treatable (Kaplan, 1999; Ferlazzo, 2010; Chicharro-Ciuffardi et al., 2012). Quantitative EEG and event-related potentials, such as mismatch negativity (MMN), can provide more subtle markers of cortical dysfunction and have been shown to be abnormal in a range of neurological and psychiatric disorders associated with cognitive deficits (John et al., 1988; Näätänen et al., 2019).

## Developmental Neurobiology

The trajectory of cognitive function in later life is profoundly shaped by events occurring throughout the lifespan, beginning in the earliest stages of brain development. The concept of neurodevelopmental origins of adult disease suggests that early life insults or genetic predispositions can create vulnerabilities that only become manifest as cognitive impairment decades later (Thibaut, 2018; Lockhart et al., 2018). This perspective is crucial for understanding the heterogeneity of Mild Neurocognitive Disorder (MND), as it highlights the roles of cognitive reserve, critical developmental periods, and the lifelong process of brain maturation and aging.

### Neurodevelopmental Origins and Cognitive Reserve

The brain's resilience to pathology is not uniform across individuals. The concept of "cognitive reserve" posits that individual differences in brain networks or cognitive processes allow some people to cope better with brain damage than others (Lara, 2017; Nelson et al., 2020). Factors that contribute to building this reserve, such as higher educational attainment, occupational complexity, and engagement in cognitively stimulating activities, are often established early in life (Lara, 2017). A higher cognitive reserve may delay the clinical expression of neurodegenerative pathology; an individual with high reserve might sustain a significant burden of Alzheimer's pathology without meeting the clinical criteria for dementia, instead presenting with MND (Willroth et al., 2022). Conversely, individuals with lower premorbid intellectual ability or educational attainment may exhibit clinical symptoms at an earlier stage of the pathological process (La Rue & Jarvik, 1987). This model helps explain why individuals with the same degree of neuropathology can have vastly different clinical presentations (Rowe & Murley, 2023).

Early life factors that disrupt normal brain development can limit the attainment of this reserve. Neurodevelopmental disorders such as intellectual disability, autism spectrum disorder, and attention-deficit/hyperactivity disorder (ADHD) are characterized by impairments in the acquisition of cognitive, language, motor, or social skills from an early age (Patel & Merrick, 2020; Helbig & Goldberg, 2021). These disorders arise from a complex mix of genetic and environmental factors that affect central nervous system (CNS) function during the developmental period (Patel & Merrick, 2020; Steinhausen & Gillberg, 2006). For example, children who later develop schizophrenia often show premorbid intellectual and academic deficits, suggesting an early neurodevelopmental origin for the cognitive impairment that is a core feature of the illness (O’Donnell, 2007; Remschmidt & Theisen, 2012). Similarly, delayed mental development (DMD) is characterized by uneven development of cognitive activity, which can impact later learning and adaptation (Kulagina & Puskaeva, 1990).

### Critical and Sensitive Periods

Brain development is not a linear process but occurs in stages, with specific "critical" or "sensitive" periods during which neural circuits are particularly malleable and susceptible to environmental influences (Almll & Finger, 2014). Experiences during these periods can have profound and lasting effects on brain structure and function (Lockhart et al., 2018). For example, exposure to neurotoxic substances, malnutrition, or severe psychosocial stress during prenatal or early postnatal development can lead to permanent alterations in brain architecture and neurochemical systems, increasing vulnerability to later-life psychiatric and cognitive disorders (Davison, 1977; Dubovický, 2010; Rothenberger & Hüther, 1997). Adolescence represents another critical period of dynamic brain maturation, particularly in prefrontal cortical regions responsible for executive functions (Lockhart et al., 2018). Substance abuse or significant stress during this time can disrupt these maturational processes and may increase the risk for developing disorders like addiction or schizophrenia in young adulthood (Sawa & Niwa, 2018; Chen & Murray, 2004).

The concept of critical periods also applies to recovery from brain injury. The immature brain was once thought to have a greater capacity for plasticity and reorganization, but evidence suggests this is not always the case (Vargha‐Khadem, 2001). Early-acquired brain damage, such as severe traumatic brain injury (TBI) in young children, can lead to more severe and widespread long-term cognitive deficits than similar injuries in adults, as the injury disrupts the ongoing developmental trajectory (Bonnier et al., 2007; Boissel, 2016). The timing of the insult is crucial; perinatal hypoxic-ischemic events, for instance, can lead to selective hippocampal damage resulting in "developmental amnesia," a specific impairment of episodic memory that becomes apparent as the child ages (Sans Fitó et al., 2011; Miller & Latal, 2009).

### Aging, Neuroplasticity, and Vulnerability

Normal aging is associated with a gradual decline in certain cognitive functions, particularly those related to processing speed and new learning, which reflects subtle, age-related neuroanatomic and neurochemical changes (Morris & McManus, 1991; Gounard & Hulicka, 1977). This process of "terminal decline" can accelerate in the years preceding death (Cowl, 2015). However, pathological aging, as seen in MND, involves a more rapid and severe decline that is not an extension of the normal aging process (Ibrahim & Amar, 2007). The aging brain becomes more vulnerable to a variety of insults. The cumulative effects of vascular risk factors, metabolic disturbances, and oxidative stress can lower the threshold for cognitive impairment (Boytsov & Samorodskaya, 2022). Furthermore, the brain's capacity for adaptive neuroplasticity—the ability to reorganize and form new synaptic connections in response to experience or injury—may diminish with age (Gynther et al., 1998). While plasticity can occur in the adult neocortex, it may be less efficient than during developmental critical periods (Gynther et al., 1998; 1998). This reduced plasticity, combined with a potential decline in cognitive reserve and the accumulation of age-related pathologies, creates a state of increased vulnerability where a "second hit," such as a medical illness, surgery, or new medication, can precipitate a significant cognitive decline or unmask a previously subclinical neurodegenerative process (Breuer et al., 2016). Thus, the emergence of MND in later life can be seen as the culmination of a lifetime of interactions between developmental programming, genetic risk, and accumulating environmental and pathological insults.

## Treatment Mechanisms

The management of Mild Neurocognitive Disorder is multifaceted, reflecting its diverse etiologies and the complexity of its underlying biological mechanisms. While there are currently no treatments approved specifically to reverse or halt the progression of MND itself, therapeutic strategies focus on three main areas: (1) treating the underlying cause, if identifiable and reversible; (2) symptomatic treatment of cognitive and neuropsychiatric symptoms, primarily borrowed from the management of dementia; and (3) non-pharmacological interventions aimed at enhancing cognitive function and promoting brain health (Kristan & Santos, 2022; Bullock, 2005). The biological basis of these interventions targets the neurochemical, cellular, and network-level dysfunctions discussed previously.

### Pharmacological Interventions

Pharmacotherapy for MND is largely off-label and based on treatments for conditions known to cause or co-occur with cognitive impairment, such as Alzheimer's disease (AD) and depression (Kristan & Santos, 2022).

**Cholinesterase Inhibitors and NMDA Receptor Antagonists:** For individuals with amnestic MND, which is often a precursor to AD, cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) are sometimes considered (Jones et al., 2016). These drugs work by inhibiting the breakdown of acetylcholine, thereby increasing its availability in the synaptic cleft (Rucci & Feinstein, 2014; Vally & Kathrada, 2019). This mechanism aims to temporarily compensate for the cholinergic deficit that characterizes AD, offering modest and short-term stabilization of cognitive function (Dickerson & Sperling, 2007; Gray et al., 1994). Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is also used in moderate-to-severe AD and works by modulating the glutamatergic system to protect against excitotoxicity (Vally & Kathrada, 2019; Jones et al., 2016). While these drugs are approved for AD, their efficacy in the MCI stage is controversial, with studies showing only marginal benefits that must be weighed against potential side effects (Jones et al., 2016; Bredesen et al., 2024).

**Antidepressants:** Given the high comorbidity between depression and MND, and the fact that depression itself can cause or mimic cognitive deficits (a condition sometimes termed "pseudodementia"), treating depressive symptoms is a critical component of management (Wilkins, 2008; Ronchetto & Ronchetto, 2022). Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line treatments (Knight et al., 2019; Forlenza, 2000). By modulating serotonergic and noradrenergic systems, these agents can alleviate mood symptoms, which may in turn lead to improvements in attention, motivation, and subjective memory complaints (Richardson & Adams, 2018; Greden, 2003). Some evidence suggests that certain antidepressants may have direct pro-cognitive effects independent of their impact on mood, possibly through mechanisms involving neurogenesis or reduction of neuroinflammation (Knight et al., 2019; Yan et al., 2011). However, it is also crucial to be aware that some psychotropic medications, particularly those with anticholinergic properties, can worsen cognition (Kojima & Akishita, 2016; Stoner et al., 2020).

**Other Pharmacological Approaches:** A variety of other agents are being investigated for their potential to enhance cognition or provide neuroprotection. Nootropic drugs, for instance, have been studied for their effects on cognitive decline, although evidence for their efficacy remains limited and often derives from methodologically flawed studies of short duration (Gray et al., 1994). For cognitive impairment related to specific conditions, such as multiple sclerosis or Parkinson's disease, different strategies are employed. In Parkinson's disease, optimizing dopaminergic therapy can sometimes improve executive functions, though responses are variable (Leiva Santana & Álvarez Saúco, 2006). For substance-induced cognitive deficits, the primary intervention is abstinence, which can lead to partial or significant recovery of function over time (Nixon & Phillips, 1999; Kleinknecht & Goldstein, 1972).

### Non-Pharmacological Interventions and Neuroplasticity

Non-pharmacological approaches are increasingly recognized as essential components of managing MND, aiming to harness the brain's inherent capacity for neuroplasticity to maintain or improve cognitive function (Castillo et al., 2020). Neuroplasticity refers to the brain's ability to modify its structure and function in response to experience, a process that can be either adaptive or maladaptive (Gynther et al., 1998; Wolf, 2002). Therapeutic interventions seek to promote adaptive plasticity.

**Cognitive Rehabilitation and Training:** Cognitive rehabilitation aims to reduce the impact of cognitive deficits on daily life by teaching compensatory strategies (Bindschaedler, 2020; Collette & Salmon, 2014). This might involve using memory aids, organizational tools, or breaking down complex tasks into simpler steps. Cognitive training, in contrast, involves structured practice on specific cognitive tasks with the goal of improving performance in the trained domain (e.g., attention, working memory) (Knight et al., 2019). The biological basis for these interventions is the principle of activity-dependent plasticity: intensively used synaptic pathways may be strengthened, potentially leading to functional reorganization of neural circuits (Gynther et al., 1998; 1998). While evidence for the long-term efficacy and generalizability of these techniques is still developing, they are considered a core part of a comprehensive management plan (Ruiz-Tagle et al., 2021; De Wit & Kessels, 2024).

**Physical Activity and Lifestyle Factors:** There is strong evidence that regular physical activity has a protective effect on brain health and can improve cognitive function (Smith et al., 2013). Exercise is thought to exert its benefits through multiple mechanisms, including improving cerebral blood flow, reducing vascular risk factors, decreasing neuroinflammation, and promoting the expression of neurotrophic factors like brain-derived neurotrophic factor (BDNF), which supports neuronal survival and neurogenesis (Senzaki, 2018; Yan et al., 2011). Diet is another modifiable factor, with adherence to patterns like the Mediterranean diet being associated with a reduced risk of cognitive decline (Vlachos, 2022). These lifestyle interventions are low-cost, low-risk strategies that can be broadly recommended to individuals with MND to promote overall brain health and potentially slow the rate of decline (Kristan & Santos, 2022; Novikova & Захаров, 2021).

## Future Directions

The study of Mild Neurocognitive Disorder (MND) stands at a critical juncture, bridging the gap between normal cognitive aging and the devastating progression to dementia. While significant strides have been made in characterizing the clinical syndrome and identifying its diverse underlying pathologies, numerous questions remain unanswered, and the field is poised for significant advancements. Future research must focus on refining diagnostic precision, elucidating fundamental biological mechanisms, and developing effective, targeted interventions.

A primary challenge is the inherent heterogeneity of MND (Presečki et al., 2014; Munro, 2018). The current diagnostic framework, while clinically useful, encompasses a wide range of etiologies, from early-stage neurodegenerative diseases to vascular pathologies, metabolic disturbances, and even functional cognitive disorders (Presečki et al., 2014; Ball et al., 2020). A crucial future direction is the development and validation of robust biomarkers to disentangle this heterogeneity at an early stage. This includes advancing neuroimaging techniques to detect subtle, pathology-specific patterns of atrophy or functional disruption (Bertrand et al., 2018; Yan et al., 2022), refining cerebrospinal fluid and blood-based assays for proteins like amyloid-beta and tau (Kozaki, 2018), and exploring novel markers related to neuroinflammation, synaptic dysfunction, and oxidative stress (Kapczinski, 2015; Maes et al., 2024). Such biomarkers are essential not only for accurate etiological diagnosis but also for tracking disease progression and measuring the response to therapeutic interventions in clinical trials (Sander, 2015).

Understanding the precise molecular and cellular mechanisms that drive the transition from a preclinical state to symptomatic MND is another vital area of research. Longitudinal studies are needed to map the temporal evolution of pathological processes like protein aggregation, neuroinflammation, and mitochondrial dysfunction in relation to the emergence of cognitive symptoms (Sadowski, 2010; Jack et al., 2010). Elucidating the interplay between genetic risk factors and environmental or lifestyle influences will be key to identifying individuals at highest risk and developing targeted prevention strategies (Lara, 2017; Ivlieva, 2011). Research into the mechanisms of cognitive reserve and resilience—why some individuals maintain cognitive function despite significant brain pathology—is of paramount importance, as it may reveal endogenous neuroprotective pathways that could be harnessed therapeutically (Rowe & Murley, 2023; Willroth et al., 2022).

The ultimate goal is the development of disease-modifying therapies that can halt or slow the neurodegenerative process at the MND stage, before irreversible and widespread neuronal loss has occurred (Bullock, 2005; Cummings & Zhong, 2017). This requires moving beyond purely symptomatic treatments, such as cholinesterase inhibitors, which offer only modest and temporary benefits (Gray et al., 1994). Future pharmacological strategies will likely target the fundamental pathological cascades, including amyloid and tau pathology, neuroinflammation, and synaptic failure (Jain, 2019; Lieberman et al., 2007). The disappointing results of many recent trials targeting single pathways highlight the need for a more nuanced approach, potentially involving combination therapies that address the multiple, interacting mechanisms of neurodegeneration (Bredesen et al., 2024).

Furthermore, there is a pressing need for rigorous, large-scale clinical trials to evaluate the efficacy of non-pharmacological interventions. While cognitive training, physical exercise, and dietary modifications show promise, their optimal intensity, duration, and long-term impact on cognitive trajectories and conversion to dementia require further clarification (Ruiz-Tagle et al., 2021; Smith et al., 2013). Integrating these non-pharmacological approaches with emerging pharmacological treatments may offer the most effective strategy for managing MND. Finally, the concept of functional cognitive disorder (FCD), where cognitive symptoms are present without a neurodegenerative basis, represents an important and under-researched area (Ball et al., 2020). Differentiating FCD from prodromal dementia is a significant diagnostic challenge that has implications for prognosis and treatment. Future research should focus on developing positive diagnostic criteria for FCD and establishing effective, evidence-based treatments, which are likely to differ substantially from those for neurodegenerative MND.

## Conclusion

Mild Neurocognitive Disorder represents a critical, albeit heterogeneous, clinical syndrome situated at the crossroads of normal aging and dementia. Its biological and neurological foundations are not rooted in a single pathology but rather in a complex and varied landscape of underlying processes. The cognitive decline observed in MND can be the earliest clinical expression of insidious neurodegenerative diseases such as Alzheimer’s disease, frontotemporal dementia, or Lewy body dementia, each characterized by distinct patterns of proteinopathy, neuronal loss, and network disruption (Presečki et al., 2014; Dickerson & Sperling, 2007; Kerchner & Rosenbloom, 2014). It can also arise from cerebrovascular disease, traumatic brain injury, systemic medical conditions, or the effects of medications and substances, all of which compromise neuronal integrity through mechanisms like ischemia, neuroinflammation, and metabolic derangement (Novikova & Захаров, 2021; Kanellopoulos & Vallejo, 2019).

The neurobiological narrative of MND is one of disrupted connectivity and failing compensation. Key neurotransmitter systems—cholinergic, dopaminergic, glutamatergic, and monoaminergic—become dysregulated, impairing the chemical signaling essential for memory, executive function, and mood (Galasko, 2019; Martínez‐Castrillo et al., 2011). At the cellular level, processes such as oxidative stress, mitochondrial dysfunction, and apoptosis contribute to a progressive loss of synapses and neurons, eroding the brain's functional capacity (Agid & Blin, 2007; Yang et al., 2021). These pathologies manifest at the systems level as measurable brain atrophy and altered functional connectivity within large-scale networks, such as the default mode and executive control networks, which can be visualized with advanced neuroimaging techniques (Dickerson & Sperling, 2007; Bertrand et al., 2018).

The clinical onset and progression of MND are further modulated by an individual's lifelong neurodevelopmental trajectory and cognitive reserve (Lara, 2017). Factors from early life, including education and genetic predispositions, interact with later-life insults to determine an individual's resilience to underlying brain pathology (Rowe & Murley, 2023). This multifactorial nature explains why some individuals progress rapidly to dementia while others remain stable or even improve (Munro, 2018).

While our understanding of these mechanisms has led to the development of symptomatic treatments and promising non-pharmacological interventions that aim to bolster cognitive reserve and harness neuroplasticity, a cure remains elusive (Kristan & Santos, 2022; Ruiz-Tagle et al., 2021). The challenge for the future lies in translating our growing biological knowledge into effective, disease-modifying therapies. This will require the refinement of early diagnostic biomarkers, a deeper understanding of the specific molecular cascades that initiate and propel neurodegeneration, and a personalized medicine approach that targets the specific etiology underlying the cognitive impairment in each individual. In essence, comprehending the biology of Mild Neurocognitive Disorder is not merely an academic exercise; it is the fundamental basis upon which we can build strategies to preserve cognitive health and improve the quality of life for an aging global population.

## References

1. Abdallah, S., Church, E., Levin, J. B., Chela, A., & McVoy, M. (2024). Short- and Long-Term Outcomes of Suboptimal Medication Adherence in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Literature Review. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2024.0018
2. Af, S., Haddad, P., Em, K., Lejoyeux, M., Jf, R., Ah, Y., & Zajecka, J. (1997). Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel.. PubMed.
3. Agid, Y., & Blin, J. (2007). Nerve Cell Death in Degenerative Diseases of the Central Nervous System: Clinical Aspects. Novartis Foundation symposium. https://doi.org/10.1002/9780470513422.ch2
4. Aguzzi, E. A. (2021). A neuroprotective strategy to reduce acute and chronic disability, and slowly progressive central nervous system atrophy in a new model of multiple sclerosis. Doctoral thesis, UCL (University College London)..
5. Akiskal, H. S. (1982). Factors associated with incomplete recovery in primary depressive illness.. PubMed.
6. Al-Khateeb, A., & Alomar, M. J. (2017). Subdural Hematoma and Delirium Case Evaluation in Elderly Patients. Journal of Young Pharmacists. https://doi.org/10.5530/jyp.2017.9.59
7. Albrecht, B., Sandersleben, H. U.-V., Gevensleben, H., & Rothenberger, A. (2015). Pathophysiology of ADHD and associated problems—starting points for NF interventions?. Frontiers in Human Neuroscience. https://doi.org/10.3389/fnhum.2015.00359
8. Albrecht, S., Leineweber, C., Ojajärvi, A., Oksanen, T., Kecklund, G., & Härmä, M. (2020). Association of work-time control with sickness absence due to musculoskeletal and mental disorders: An occupational cohort study. Journal of Occupational Health. https://doi.org/10.1002/1348-9585.12181
9. Alesci, R. S., Hecking, C., Weissmann, M. V., & Dempfle, C. (2024). Identification of an Unmet Medical Need – Height of Depression, Hypersomnia and Sleep Apnea Positively Correlate with the Level of Fatigue in Patients with Immune Thrombocytopenia. Hämostaseologie. https://doi.org/10.1055/s-0044-1779171
10. Alexander, J. L., Sommer, B., Dennerstein, L., Grigorova, M., Neylan, T. C., Kotz, K., Richardson, G., & Rosenbaum, R. (2007). Role of psychiatric comorbidity on cognitive function during and after the menopausal transition. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.7.11s.s157
11. Alfradique, I., & Vasconcelos, M. M. (2007). Juvenile myoclonic epilepsy. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2007000700036
12. Alici, Y., & Breitbart, W. (2021). Delirium. CRC Press eBooks. https://doi.org/10.1201/9780429275524-47
13. Almannai, M., Dai, H., El‐Hattab, A. W., & Wong, L. C. (2017). FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion Syndrome.
14. Ambikar, D., Melese, E., & Patil, M. J. (2018). Influence of Unani polyherbal formulation on learning and memory retention in mice. Deleted Journal. https://doi.org/10.29090/psa.2018.03.174
15. Amihăesei, I. C., & Cojocaru, E. (2014). Main neuroendocrine features, diagnosis and therapeutic possibilities in the chronic fatigue syndrome, an underdiagnosed entity.. PubMed.
16. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
17. anand, I., & Rawal, K. (2022). drug_doc_human_documentation. https://doi.org/10.31219/osf.io/3dnhz
18. Andrabi, S. M., Alam, S., Zia, A., Khan, M. H., & Kumar, A. (2014). Mental nerve paresthesia secondary to initiation of endodontic therapy: a case report. Restorative Dentistry & Endodontics. https://doi.org/10.5395/rde.2014.39.3.215
19. Andrade, C. (2004). Antidepressant-Withdrawal Mania. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v65n0716
20. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
21. Andrews, G., Brugha, T., Thase, M. E., Duffy, F. F., Rucci, P., & Slade, T. (2007). Dimensionality and the category of major depressive episode. International Journal of Methods in Psychiatric Research. https://doi.org/10.1002/mpr.216
22. Andrews, G., Stewart, G., Morris‐Yates, A., Holt, P. E., & Henderson, S. (1990). Evidence for a General Neurotic Syndrome. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.157.1.6
23. Andrès, E. (2021). Mild Cognitive Impairment is a Condition in Which a Person Experiences a Slight but Noticeable Decline in Mental Abilities Compared with others of the Same Age. Journal of Aging and Geriatric Medicine.
24. Ankar, R., & Singh, S. (2020). Chemotherapy Induced Peripheral Neuropathy – A Review. Journal of Evolution of Medical and Dental Sciences. https://doi.org/10.14260/jemds/2020/689
25. Ankolekar, S. (2020). Study of Adverse drug reactions and its Mechanisms. Cell & Developmental Biology.
26. Anuzyte, J. S., Rutkauskaitė, G., & Mameniškienė, R. (2018). Transient epileptic amnesia. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.26
27. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
28. Arnone, J. M., & Conti, R. P. (2016). Kleine-Levin Syndrome: An Overview and Relevance to Nursing Practice. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20160219-07
29. Arrowsmith, J. E. (2010). Central nervous system. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199209101.003.05
30. Arsanti, N. M., & Wreksoatmodjo, B. R. (2025). Tata Laksana Gangguan Kognitif di Layanan Primer. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v52i9.1653
31. Arzimanoglou, A., & Cross, J. H. (2019). Cognitive impairment and behavioral disorders in Encephalopathy related to Status Epilepticus during slow Sleep: diagnostic assessment and outcome. Epileptic Disorders. https://doi.org/10.1684/epd.2019.1060
32. Asadi‐Pooya, A. A., & Sperling, M. R. (2009). Aggravation of Seizures by Antiepileptic Drugs. https://doi.org/10.1093/oso/9780195368215.003.0007
33. Ascoli, M., Ferlazzo, E., Gasparini, S., Mastroianni, G., Citraro, R., Roberti, R., & Russo, E. (2021). Epidemiology and Outcomes of Status Epilepticus. International Journal of General Medicine. https://doi.org/10.2147/ijgm.s295855
34. Autor, J. L. M. C., & Principal, C. M. A. C. O. T. (2018). Demencia tipo Alzheimer vs pseudo demencia por depresión. Estudio neuropsicológico de un caso. XII CONGRESO DE POSGRADO EN PSICOLOGÍA | UNAM | 2018.
35. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
36. Avari, J., Yuen, G. S., AbdelMalak, B., Mahgoub, N., Kalayam, B., & Alexopoulos, G. S. (2014). Assessment and Management of Late-Life Depression. Psychiatric Annals. https://doi.org/10.3928/00485713-20140306-04
37. Avidan, M. S., & Evers, A. S. (2011). Review of Clinical Evidence for Persistent Cognitive Decline or Incident Dementia Attributable to Surgery or General Anesthesia. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-2011-101680
38. Ay, D. (2010). A Case of Transient Global Amnesia due to Marijuana Use. Journal of Academic Emergency Medicine. https://doi.org/10.4170/jaem.2010.40085
39. Baandrup, L., Jennum, P., Lublin, H., & Glenthøj, B. (2012). Treatment options for residual insomnia in schizophrenia. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12016
40. Bainbridge, W., Berron, D., Schütze, H., Cárdenas‐Blanco, A., Metzger, C. D., Dobisch, L., Bittner, D., Glanz, W., Spottke, A., Rudolph, J., Brosseron, F., Büerger, K., Janowitz, D., Fließbach, K., Heneka, M. T., Laske, C., Buchmann, M., Peters, O., Diesing, D., ... Düzel, E. (2019). Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2019.07.005
41. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
42. Baldessarini, R. J. (1988). Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800250095013
43. Balhara, Y. P. S., Mohan, I., Sagar, R., & Chawla, J. (2006). Chronic mania: An unexpectidly long episode?. Indian Journal of Medical Sciences. https://doi.org/10.4103/0019-5359.25681
44. Balhara, Y. S., Verma, R., & Mathur, S. (2011). Management of attention-deficit hyperactivity disorder. Journal of Pediatric Neurosciences. https://doi.org/10.4103/1817-1745.84400
45. Ball, H. A., McWhirter, L., Ballard, C., Bhome, R., Blackburn, D., Edwards, M. J., Fleming, S. M., Fox, N. C., Howard, R., Huntley, J., Isaacs, J. D., Larner, A. J., Nicholson, T. R., Pennington, C., Poole, N., Price, G., Price, J. P., Reuber, M., Ritchie, C., ... Carson, A. (2020). Functional cognitive disorder: dementia’s blind spot. Brain. https://doi.org/10.1093/brain/awaa224
46. Barbosa, T. A., Machado, R. R., Moeda, A. S. G., Gloria, I. R., Shidiq, S., & Brandão, P. (2023). Importância da hidrocefalia como diagnóstico diferencial de síndromes demenciais. Congresso Médico Acadêmico UniFOA.. https://doi.org/10.47385/cmedunifoa.315.5.2018
47. Bates, D. O. (2020). The unconscious patient. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0579
48. Battaglia, J., Robinson, D. G., & Citrome, L. (2007). The Treatment of Acute Agitation in Schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852900026146
49. Baweja, R., Sedky, K., & Lippmann, S. (2010). Clozapine associated delirium. Eastern Journal Of Medicine.
50. Baxter, P. (2015). States of consciousness: new insights and further questions. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.12666
51. Bebek, N., & Ertaş, M. (2007). [Neuropathic pain].. PubMed.
52. Beghi, E., & Hauser, W. A. (2008). First seizure definitions and worldwide incidence and mortality. Epilepsia. https://doi.org/10.1111/j.1528-1167.2008.01443.x
53. Bekker, A. (2014). Postoperative cognitive decline in the elderly. Surgery Current Research.
54. Bencze, J., Simon, V., Bereczki, E., Majer, R., Varkoly, G., Murnyák, B., Kálmán, J., & Hortobágyi, T. (2017). A Lewy-testes demencia klinikai és neuropatológiai jellemzői | Clinical and neuropathological characteristics of dementia with Lewy bodies.
55. Bernardin, F., Maheut-Bosser, A., & Paille, F. (2014). Cognitive Impairments in Alcohol-Dependent Subjects. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2014.00078
56. Bernardin, F., Maheut-Bosser, A., & Paillé, F. (2014). [Cognitive impairment of alcohol-dependent subjects].. PubMed.
57. Bertrand, E., Azar, M., Rizvi, B., Brickman, A. M., Huey, E. D., Habeck, C., Landeira-Fernandez, J., Mograbi, D. C., & Cosentino, S. (2018). Cortical thickness and metacognition in cognitively diverse older adults.. Neuropsychology. https://doi.org/10.1037/neu0000458
58. Bhat, K., Pandita, K. K., Bhat, S., & Gupta, S. (2013). Atypical neuroleptic malignant syndrome. &amp;#147;Doing more harm than gain&amp;#148;. International Journal of Research in Medical Sciences. https://doi.org/10.5455/2320-6012.ijrms20131157
59. Bibi, E. S. D. M. (2021). AN OVERVIEW OF POST WAR SOCIAL PROBLEMS IN SYRIA. Pakistan Journal of International Affairs. https://doi.org/10.52337/pjia.v2i2.63
60. Bigio, M. R. D. (2021). Neuronal Death. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.030
61. Bindschaedler, C. (2020). [Episodic and prospective memory impairment: impact, assessment and cognitive rehabilitation].. PubMed.
62. Biswas, S., Raju, N. S. G., & Patel, K. R. (2015). Should Non-psychiatrists Be Trained to Recognize and Treat Co-morbid Depression?. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31023-3
63. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
64. Blok, A., Verduyn, T. J., Vergouwen, A. C. M., & Weinstein, H. C. (2005). [Disorders of concentration and memory in young adults and middle-aged persons]..
65. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
66. Boeker, H., Schulze, J. B., Richter, A., Nikisch, G., Schuepbach, D., & Grimm, S. (2012). Sustained Cognitive Impairments After Clinical Recovery of Severe Depression. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/nmd.0b013e318266ba14
67. Boissel, A. (2016). Brain-injured Adolescents. Adolescence.
68. Bolfer, C. P. M., Casella, E. B., Baldo, M. V. C., Mota, A., Tsunemi, M. H., Pacheco, S. P., & Reed, U. C. (2010). Reaction time assessment in children with ADHD. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2010000200025
69. Bonnet, M. H., & Arand, D. L. (2008). Chronic insomnia. CRC Press eBooks. https://doi.org/10.3109/9780203091715-12
70. Bonnier, C., Marique, P., Hout, A. V., & Potelle, D. (2007). Neurodevelopmental Outcome After Severe Traumatic Brain Injury in Very Young Children: Role for Subcortical Lesions. Journal of Child Neurology. https://doi.org/10.1177/0883073807302604
71. Boon, P., Breuer, L. E. M., Grevers, E., Bernas, A., Bergmans, J., Besseling, R. M., Klooster, D., Louw, A. D., Mestrom, R., Vonck, K., Zinger, S., & Aldenkamp, A. P. (2016). Cognitive deterioration in adult epilepsy: clinical characteristics of “Accelerated Cognitive Ageing”. Acta Neurologica Scandinavica. https://doi.org/10.1111/ane.12700
72. Bosisio, A. C. M. (2004). Acute Confusional State. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508434.003.0022
73. Bouffet, É., McGee, P., & Beal, D. S. (2004). Pediatric Neurology. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508434.003.0011
74. Bouritius, E. M., Neven, A. K., & Blom, J. D. (2015). [Alcohol hallucinosis].. PubMed.
75. Boytsov, S. А., & Samorodskaya, I. V. (2022). Cardiovascular disease and cognitive impairment. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro20221220717
76. Bradley, K., & Robins, H. I. (2007). Neurologic Complications of Therapy. ONCOLOGY. https://doi.org/10.1007/0-387-31056-8_79
77. Brancaccio, D., Damasso, R., Spinnler, H., Sterzi, R., & Vallar, G. (1981). Does Chronic Kidney Failure Lead to Mental Failure?. Archives of Neurology. https://doi.org/10.1001/archneur.1981.00510120057008
78. Bredesen, D. E., Ross, M. K., & Ross, S. R. (2024). Sustained Cognitive Improvement in Alzheimer’s Disease Patients Following a Precision Medicine Protocol: Case Series. Biomedicines. https://doi.org/10.3390/biomedicines12081776
79. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
80. Brust, J. C. (1999). Substance Abuse, Neurobiology, and Ideology. Archives of Neurology. https://doi.org/10.1001/archneur.56.12.1528
81. Brás, J., Sousa, R. C. D., Costa, A. L., Melo, B., Marques, A., Teixeira, D., Pereira, C. A., & Cunha, N. (2019). A CASE OF NEUROLEPTIC MALIGNANT SYNDROME: A NEUROLOGIC EMERGENCY DUE TO PSYCHOTROPIC DRUGS. https://doi.org/10.26226/morressier.5d1a037357558b317a140392
82. Buckley, P. F., Foster, A., Patel, N. C., & Wermert, A. (2009). Adherence and the societal burden of mental illness. https://doi.org/10.1093/oso/9780195384338.003.0001
83. Buckley, P., & Brown, E. S. (2006). Prevalence and Consequences of Dual Diagnosis. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.0706e01
84. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
85. Buhmann, C., Huckhagel, T., Engel, K., Gulberti, A., Hidding, U., Poetter-Nerger, M., Goerendt, I., Ludewig, P., Braaß, H., Choe, C., Krajewski, K., Oehlwein, C., Mittmann, K., Engel, A. K., Gerloff, C., Westphal, M., Köppen, J. A., Moll, C. K., & Hamel, W. (2017). Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences. PLoS ONE. https://doi.org/10.1371/journal.pone.0178984
86. Bullock, R. (2005). Treatment. CRC Press eBooks. https://doi.org/10.1201/b13239-34
87. Buompadre, M. C. (2018). [Status epilepticus].. PubMed.
88. Byrne, A., Byrne, M. K., & Zibin, T. (1993). Transient neurogenic stuttering. International Journal of Eating Disorders. https://doi.org/10.1002/1098-108x(199312)14:4<511::aid-eat2260140416>3.0.co;2-l
89. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Le retard mental. Le point sur... Psychologie.
90. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
91. Ca, H., Haan, D., Wa, H., Ar, K., Aj, R., & Pm, D. J. (1986). Severity and duration of obsessive-compulsive complaints. Results of treatment.. PubMed.
92. Cabé, N., Lanièpce, A., Boudehent, C., Vabret, F., & Pitel, A. (2019). [Alcohol induced neurocognitive disorder: screening strategies and tools].. HAL (Le Centre pour la Communication Scientifique Directe).
93. Cadet, J. L., & Bolla, K. I. (1996). Chronic cocaine use as a neuropsychiatric syndrome: A model for debate. Synapse. https://doi.org/10.1002/(sici)1098-2396(199601)22:1<28::aid-syn3>3.0.co;2-k
94. Cadet, J. L., & Bolla, K. I. (1996). Chronic cocaine use as a neuropsychiatric syndrome: A model for debate. Synapse. https://doi.org/10.1002/(sici)1098-2396(199601)22:1<28::aid-syn3>3.3.co;2-k
95. Cambra, P. R. (2021). Trastorno mental grave, pacientes con esquizofrenia.. Revista Sanitaria de Investigación.
96. Campoy, A. T., Rotger, M. Y., Gutiérrez, L. R. D. L. H., & Pastorelli, R. V. (2011). ¿Psicosis mental injertada o retraso mental? A propósito de un caso.. Psiquiatria.com.
97. Cao, F., Salem, H., Nagpal, C., & Teixeira, A. L. (2017). Prolonged delirium misdiagnosed as a mood disorder. Dementia & Neuropsychologia. https://doi.org/10.1590/1980-57642016dn11-020014
98. Casher, M. I., & Bess, J. D. (2020). The Inpatient with Dual Diagnosis (Co-Occurring Disorder). Cambridge University Press eBooks. https://doi.org/10.1017/9781108656672.009
99. Casper, R. C. (2018). Not the Function of Eating, but Spontaneous Activity and Energy Expenditure, Reflected in “Restlessness” and a “Drive for Activity” Appear to Be Dysregulated in Anorexia Nervosa: Treatment Implications. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2018.02303
100. Cassidy‐Eagle, E., & Siebern, A. (2017). Sleep and mild cognitive impairment. Sleep Science and Practice. https://doi.org/10.1186/s41606-017-0016-5
101. Castellanos, G., Escobar, A. P., & González, B. G. (2006). Estrés y conducta adictiva. DELETED.
102. Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., López‐Chozas, J. M., & Fernández‐Bolaños, R. (2006). Electrolytes Disturbances and Seizures. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00861.x
103. Castillo, G., Fernández, B., & Chamorro, D. (2020). Neuroplasticidad: Ejercicios para retrasar los efectos de la Enfermedad de Alzheimer mediante Estimulación Cognitiva. Revista de Investigación Científica y Tecnológica. https://doi.org/10.36003/rev.investig.cient.tecnol.v4n2(2020)12
104. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
105. Chan, D. K. Y., & Brennan, N. (1999). Delirium: making the diagnosis, improving the prognosis.. PubMed.
106. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
107. Charante, E. P. M. V., Richard, E., & Perry, M. (2022). [Forgetfulness].. PubMed.
108. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
109. Chattopadhyay, S., Nm, P., Nayak, R., & Chate, S. (2012). Cognitive deficits in schizophrenia. Journal of the Scientific Society. https://doi.org/10.4103/0974-5009.101842
110. Chaudhry, S. (2020). Depression and its Dilemma. IP Journal of Surgery and Allied Sciences. https://doi.org/10.18231/j.jsas.2020.013
111. Chavarría, A. C. M., Dardón, W. R. G., & Díaz, M. O. H. (2022). TDAH y su relación con eventos cerebrovasculares a futuro. Revista Académica Sociedad del Conocimiento Cunzac. https://doi.org/10.46780/sociedadcunzac.v2i2.45
112. Chen, C., Leys, D., & Esquenazi, A. (2013). The interaction between neuropsychological and motor deficits in patients after stroke. Neurology. https://doi.org/10.1212/wnl.0b013e3182762569
113. Chen, C.-K., & Murray, R. (2004). How does drug abuse interact with familial and developmental factors in the etiology of schizophrenia?. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511735103.016
114. Chicharro-Ciuffardi, A., González-Silva, M., Marinis-Palombo, A. D., & Gabler-Santalices, G. (2012). Psychiatric disorders secondary to nonconvulsive status epilepticus of frontal origin. Two clinical case reports.. PubMed.
115. Choi‐Kwon, S., & Kim, J. S. (2011). Poststroke Fatigue: An Emerging, Critical Issue in Stroke Medicine. International Journal of Stroke. https://doi.org/10.1111/j.1747-4949.2011.00624.x
116. Chopra, K., & Tiwari, V. (2012). Tocotrienol and Cognitive Dysfunction Induced by Alcohol. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-047-2_14
117. Chou, R., Norris, S. L., Carson, S., & Chan, B. (2007). Drug Class Review: Drugs for Neuropathic Pain: Final Report [Internet].
118. Chou, S.-T., Pogach, M., & Rock, L. K. (2022). Promoting sleep and other simple, non-pharmacological interventions for preventing and treating ICU Delirium: case report. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-1374870/v1
119. Chouinard, G., & Chouinard, V. (2015). New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000371865
120. Chummun, H., Tilley, V., & Ibe, J. (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.. British Journal of Nursing.
121. Chávez, J. J. S. (1999). El área de penumbra. Revista de Neurología. https://doi.org/10.33588/rn.2808.98245
122. Cipriani, G., Lucetti, C., Danti, S., & Nuti, A. (2014). Sleep disturbances and dementia. Psychogeriatrics. https://doi.org/10.1111/psyg.12069
123. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Consciousness disorders: vegetative state and minimally conscious state].. PubMed.
124. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Toxicant-induced and drug-induced coma neurotoxicological issues of general anesthesia].. PubMed.
125. Clancy, O., Edginton, T., Casarin, A., & Vizcaychipi, M. P. (2015). The psychological and neurocognitive consequences of critical illness. A pragmatic review of current evidence. Journal of the Intensive Care Society. https://doi.org/10.1177/1751143715569637
126. Clark, D. J., Bond, C., Andrews, A. W., Müller, D. J., Sarkisian, A., Opoka, R. O., Idro, R., Bangirana, P., Witten, A., Sausen, N., Birbeck, G. L., John, C. C., & Postels, D. G. (2023). Admission Clinical and EEG Features Associated With Mortality and Long-term Neurologic and Cognitive Outcomes in Pediatric Cerebral Malaria. Neurology. https://doi.org/10.1212/wnl.0000000000207657
127. Clark, M., & McKinlay, J. (2009). Coma, Confusion, and Agitation in Intensive Care. Competency-based critical care. https://doi.org/10.1007/978-1-84882-070-8_11
128. Cock, H. R., & Edwards, M. J. (2018). Functional neurological disorders: acute presentations and management. Clinical Medicine. https://doi.org/10.7861/clinmedicine.18-5-414
129. Coelho, L. R. P., Batista, L. R., Silva, A. C. B., Ramos, A. C. R., Fagundes, L. M., Barros, B. E., Belfort, R. L. D. A., Vieira, M. R. V., Cavalcanti, A. T. L., & Silva, R. R. C. (2024). Diferenciação diagnóstica de crises neurológicas: Epilepsia, Síncope, Crises Psicogênicas, Enxaqueca e Narcolepsia. Europub Journal of Health Research. https://doi.org/10.54747/ejhrv8n2-008
130. Cohen, L. J., & Brody, D. S. (2015). Frontotemporal Dementia‐Like Syndrome Following Recall of Childhood Sexual Abuse. Journal of Traumatic Stress. https://doi.org/10.1002/jts.22016
131. Cohen, S. P., & Mao, J. (2014). Neuropathic pain: mechanisms and their clinical implications. BMJ. https://doi.org/10.1136/bmj.f7656
132. Colaluca, B. (2022). Assessing and Intervening with Children who are Chronically Ill. https://doi.org/10.1002/9781119790563.ch18
133. Cole, M. G. (2013). Subsyndromal delirium in old age: conceptual and methodological issues. International Psychogeriatrics. https://doi.org/10.1017/s1041610213000434
134. Collette, F., & Salmon, É. (2014). [The effect of normal and pathological aging on cognition].. PubMed.
135. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
136. Condor, B. (2016). THE PSYCHOLOGY OF COMPLIANCE. IT Governance Publishing eBooks. https://doi.org/10.2307/j.ctt19jcgrc.17
137. Consoli, A., Carvalho, W. D., & Cohen, D. (2013). Side Effects of ECT. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199937899.003.0008
138. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
139. Cools, R., Aarts, E., & Mehta, M. A. (2011). Paradoxical effects of drugs on cognitive function: the neuropsychopharmacology of the dopamine and other neurotransmitter systems. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511978098.025
140. Coppola, G., Pastorino, G. M. G., Morcaldi, L., D’Onofrio, F., & Operto, F. F. (2020). Psychogenic Non-Epileptic Status as Refractory, Generalized Hypertonic Posturing: Report of Two Adolescents. Medicina. https://doi.org/10.3390/medicina56100508
141. Cortese, S., Bernardina, B. D., & Mouren, M. (2007). Attention-Deficit/Hyperactivity Disorder (ADHD) and Binge Eating. Nutrition Reviews. https://doi.org/10.1301/nr.2007.sept.404-411
142. Cortés, M. D. C. M. (2013). Análisis evolutivo y valoración neuropsicológica integral de pacientes con deterioro cognitivo leve o enfermedad de Alzheimer..
143. Cowl, A. (2015). Terminal Decline. The Encyclopedia of Adulthood and Aging. https://doi.org/10.1002/9781118521373.wbeaa326
144. Crews, F. T., & Vetreno, R. P. (2015). Mechanisms of neuroimmune gene induction in alcoholism. Psychopharmacology. https://doi.org/10.1007/s00213-015-3906-1
145. Cristina, L., Făget, D., Chiriță, V., Chiriță, R., & Manea, M. (2019). "Alternative therapies and management of dementia in Alzheimer's disease". Bulletin of Integrative Psychiatry. https://doi.org/10.36219/bpi.2019.04.07
146. Culpepper, L. (2015). Impact of Untreated Major Depressive Disorder on Cognition and Daily Function. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13086tx4c
147. Cummings, J. L., & Zhong, K. (2017). Promise and Challenges in Drug Development and Assessment for Cognitive Enhancers. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214401.003.0001
148. Custodio, N., Castro, S., Herrera‐Pérez, E., Lira, D., Prado, L. N. D., Cortijo, P., & Montesinos, R. (2013). Afasias progresivas primarias: las afasias de lenta evolución a demencia.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v75i3.1227
149. Custodio, N., Montesinos, R., & López‐Góngora, M. (2018). Deterioro cognitivo en pacientes con esclerosis múltiple. Anales de la Facultad de Medicina. https://doi.org/10.15381/anales.v79i4.15641
150. Cvijanović, M., Simić, S., Banic-Horvat, S., Jovin, Z., Slankamenac, P., & Ilin, M. (2011). Contemporary treatment neuropathic pain. Medicinski pregled. https://doi.org/10.2298/mpns1110443c
151. Cáceres, F., Baca, G. H. R., Osorto, L. J. R., Godoy, K. J. Á., Hernández, G. R. O., Barahona, R. D. S., Sorto, N. D. Z., Suárez, M., Anduray, A. S. M., Mendoza, K. V. J., & Vargas, G. H. R. (2024). Síndrome Convulsivo. Religación Press eBooks. https://doi.org/10.46652/religacionpress.195.c296
152. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
153. Dana, A. I. (2021). Mild Cognitive Impairment is an Early Stage of Memory Loss. Journal of Aging and Geriatric Medicine.
154. Davies, J. B., Saunders, W., & Helfgott, S. (2018). What is addiction?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0001
155. Davison, A. (1977). The Biochemistry of Brain Development and Mental Retardation. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.131.6.565
156. Debbarma, S., & Sedky, K. (2016). Narcolepsy in Adolescents: A Review and Three Case Reports. Adolescent Psychiatry. https://doi.org/10.2174/2210676606666160502130708
157. Delgado, D. A. O., Rojas, M. C. O., & Olea, J. M. S. (2024). Episodio depresivo mayor de características catatónicas: Reporte de caso. Revista Científica de Salud y Desarrollo Humano. https://doi.org/10.61368/r.s.d.h.v5i1.75
158. Delgado, F. M., Muela, S. H., Blanco, L. M. D., Mas, L. A., & Simonini, M. C. E. (2006). Dificultades del aprendizaje en los niños epilépticos. Revista de Neurología. https://doi.org/10.33588/rn.42s02.2005779
159. Delgado, M. G., & Bogousslavsky, J. (2013). Aggravation neurologique après une crise d’épilepsie post-AVC : une paralysie de Todd persistante?.
160. Dell’Osso, B., Benatti, B., Grancini, B., Vismara, M., Carlo, V. D., Cirnigliaro, G., Albert, U., & Viganò, C. (2019). Investigating duration of illness and duration of untreated illness in obsessive compulsive disorder reveals patients remain at length pharmacologically untreated. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651501.2019.1621348
161. Demey, I., Zimerman, M., Allegri, R., Serrano, C., & Taragano, F. (2004). Neuropsychiatric symptoms of mild cognitive impairment. CRC Press eBooks. https://doi.org/10.3109/9780203492857-7
162. Demyttenaere, K. (2022). The temporal experience in depression: from slowing down and delayed help seeking to the emergency setting and length of treatment. International Review of Psychiatry. https://doi.org/10.1080/09540261.2022.2141103
163. Demyttenaere, K., & Duppen, Z. V. (2018). The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyy052
164. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
165. Diaz, M. M., McCutchan, J. A., Crescini, M., Tang, B., Franklin, D., Letendre, S. L., Heaton, R. K., & Bharti, A. (2024). Longitudinal study of cognitive function in people with HIV and toxoplasmic encephalitis or latent toxoplasma infection. AIDS. https://doi.org/10.1097/qad.0000000000003992
166. Dickerson, B. C., & Sperling, R. A. (2007). Dementia: mild cognitive impairment and Alzheimer’s disease. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198566298.003.0005
167. Ding, K., Gupta, P. K., & Diaz‐Arrastia, R. (2016). Epilepsy after Traumatic Brain Injury. CRC Press, Taylor and Francis Group eBooks.
168. Dingwall, K., & Cairney, S. (2011). Recovery from Central Nervous System Changes Following Volatile Substance Misuse. Substance Use & Misuse. https://doi.org/10.3109/10826084.2011.580221
169. DipHE, O. P. M. B., & PGCert, J. L. D. R. (2017). Mental health emergencies. https://doi.org/10.1002/9781119464365.ch7
170. Dodick, D. W., & Roarke, M. C. (2007). Familial Hemiplegic Migraine: Permanent Attack‐Related Neurologic Deficits. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2007.00889.x
171. Dolenc, T. J. (2015). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214883.003.0044
172. Domoto‐Reilly, K., Sapolsky, D., & Dickerson, B. C. (2014). Mild Cognitive Impairment (MCI) Stage of the Frontotemporal Dementias: Early Diagnosis and Management. Perspectives on Gerontology. https://doi.org/10.1044/gero19.2.57
173. DRISCOLL, P. L. (2009). MAINTENANCE MEDICATION FOR CHRONIC SCHIZOPHRENICS: RISK/BENEFIT ASSESSMENT. Perspectives In Psychiatric Care. https://doi.org/10.1111/j.1744-6163.1985.tb00264.x
174. Drossel, C. (2020). Neurocognitive Disorders and Health Psychology. The Wiley Encyclopedia of Health Psychology. https://doi.org/10.1002/9781119057840.ch143
175. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
176. Duclos, C., Beauregard, M., Bottari, C., Ouellet, M., & Gosselin, N. (2014). The impact of poor sleep on cognition and activities of daily living after traumatic brain injury: A review. Australian Occupational Therapy Journal. https://doi.org/10.1111/1440-1630.12164
177. Dugan, P., Holmes, M., & Carlson, C. (2025). Adverse Effects of Antiseizure Medications: Idiosyncratic Reactions. Epilepsy. https://doi.org/10.1093/med/9780197673751.003.0013
178. Duletic, N., Mijatovic-Papic, T., Cizmovic, B., & Kusturica, S. (2015). Differential Diagnostic Consideration of the Syndrome of Psychomotor Agitation in Geriatric Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31130-5
179. Duncan, J. S. (1988). Neuropsychiatric aspects of sedative drug withdrawal. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.470030304
180. Duperrouzel, J. C., Ross, J. M., Pacheco‐Colón, I., & González, R. (2020). Psychosocial. The Wiley Encyclopedia of Health Psychology. https://doi.org/10.1002/9781119057840.ch31
181. Dutta, C. N., Christov‐Moore, L., Ombao, H., & Douglas, P. K. (2022). Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan. Frontiers in Human Neuroscience. https://doi.org/10.3389/fnhum.2022.938501
182. Díaz, M. F. G., & Pérez, L. R. (2019). Factores que intervienen en la depresión de personas con enfermedad renal crónica en tratamiento de hemodiálisis en una población mexiquense.
183. Economou, A., Papageorgiou, S. G., & Papanicolaou, A. C. (2005). Amnesias Associated with the Dementias. https://doi.org/10.1093/oso/9780195172454.003.0004
184. Edwards, G., Marshall, E. J., & Cook, C. C. H. (2003). Withdrawal states and treatment of withdrawal. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543722.018
185. Egbert, A. M. (1993). 'The dwindles'. Failure to thrive in older patients.. PubMed.
186. El‐Menyar, A., Al‐Thani, H., & Mansour, M. (2024). Dementia and traumatic brain injuries: underestimated bidirectional disorder. Frontiers in Neurology. https://doi.org/10.3389/fneur.2023.1340709
187. Ercole, A., Hutchinson, P. J., & Pickard, J. D. (2020). Brainstem death and prolonged disorders of consciousness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0580
188. Ereshefsky, L., Tran-Johnson, T., & Watanabe, M. (1990). Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.. PubMed.
189. Erickson, K. R. (1990). Amnestic disorders. Pathophysiology and patterns of memory dysfunction.. PubMed.
190. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
191. Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., Hallett, M., LaFaver, K., LaFrance, W. C., Lang, A. E., Nicholson, T. R., Nielsen, G., Reuber, M., Voon, V., Stone, J., & Morgante, F. (2018). Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2018.1264
192. Esquiliano, G. R., Ramírez, I. M., Valdés, A. T., & Aguilar, C. A. T. (2004). Daño neurológico secundario a hipoxia isquemia perinatal. Archivos de neurociencias (México, D.F.).
193. Evered, L., Atkins, K. J., Silbert, B., & Scott, D. A. (2022). Acute peri‐operative neurocognitive disorders: a narrative review. Anaesthesia. https://doi.org/10.1111/anae.15613
194. Eşkut, N., & Köşkderelioğlu, A. (2021). Neurotoxic Agents and Peripheral Neuropathy. IntechOpen eBooks. https://doi.org/10.5772/intechopen.101103
195. Faeder, M., Hale, E., Hedayati, D., Israel, A., Moschenross, D., Peterson, M., Peterson, R., Piechowicz, M., Punzi, J., & Gopalan, P. (2023). Preventing and treating delirium in clinical settings for older adults. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231198462
196. Fallon, M. (2011). Depression in End-Stage Renal Disease. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20110705-02
197. Fava, G. A. (2011). DB02-01 - Drug treatment is not necessary for maintenance treatment of depression. European Psychiatry. https://doi.org/10.1016/s0924-9338(11)73495-2
198. Fava, G. A., & Cosci, F. (2019). Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19com12794
199. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
200. FAVRE, I. M., Véran, O., Payen, I., & Vercueil, L. (2011). Transient Epileptic Amnesia: a case report and a reappraisal. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2011.0254
201. Ferlazzo, E. (2010). Confusional status epilepticus in elderly. BMC Geriatrics. https://doi.org/10.1186/1471-2318-10-s1-l35
202. Fernández, A. B., Martín, E., Marrero, R., & Viera, D. J. (2020). Myoclonus and Recurrent Cardioinhibitory Vasovagal Syncope after Abdominal Surgery in a Critical Care Setting. World Journal of Cardiovascular Diseases. https://doi.org/10.4236/wjcd.2020.105025
203. Fernández‐Torre, J. L. (2010). Estado epiléptico no convulsivo en adultos en coma. Revista de Neurología. https://doi.org/10.33588/rn.5005.2009333
204. Ferrante, F., & Grichnik, K. P. (1991). The difference between acute and chronic pain.. PubMed.
205. Ferrara, P. (2014). Child abuse and neglect: psychiatric and neuro-biological consequences. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-40-s1-a32
206. Ferrara, P., Gatto, A., Vitelli, O., Romano, V., Bufalo, F. D., Romaniello, L., & Ruggiero, A. (2008). Nocturnal Enuresis in Children: A Review of the Literature. Current Pediatric Reviews. https://doi.org/10.2174/157339608784462007
207. Ferraro, T. N., Fischer, B. D., & Buono, R. J. (2020). Genetic Causes of Medication-Resistant Epilepsy. Cambridge University Press eBooks. https://doi.org/10.1017/9781316492376.009
208. Ferreira, A. P. (2015). Prevalence and consequences of sleep disorders among traffic agents: A case study. Ciencia & trabajo. https://doi.org/10.4067/s0718-24492015000300009
209. Fields, J. A., Norman, S., Straits-Tröster, K., & Tröster, A. I. (1998). The impact of depression on memory in neurodegenerative disease. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544378.020
210. Figueiredo, J. M. D. (1993). Depression and demoralization: Phenomenologic differences and research perspectives. Comprehensive Psychiatry. https://doi.org/10.1016/0010-440x(93)90016-w
211. Finger, S., & Almll, C. R. (2014). Neural Insult and Critical Period Concepts. https://doi.org/10.4324/9781315802077-11
212. Fitten, L. J. (2015). Psychological Frailty in the Aging Patient. Nestlé Nutrition Institute Workshop series. https://doi.org/10.1159/000382060
213. Fitó, A. S., Roura, R. C., López‐Sala, A., Lluch, C. B., López, J. M., Rebollo, M., Julià, M. G., Póo, L. C., & Plana, J. C. (2011). Amnesia del desarrollo como secuela cognitiva focal de patología neonatal. Revista de Neurología. https://doi.org/10.33588/rn.52s01.2010803
214. Fjeldhøj, S., Thomsen, B. L. C., Pedersen, P. M., Jensen, S. R., Clausen, A., Karlsborg, M., Jespersen, B., Bergdal, O., & Løkkegaard, A. (2025). Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease. Journal of Parkinson s Disease. https://doi.org/10.1177/1877718x251334049
215. Flynn, F. G. (2010). MEMORY IMPAIRMENT AFTER MILD TRAUMATIC BRAIN INJURY. CONTINUUM Lifelong Learning in Neurology. https://doi.org/10.1212/01.con.0000391454.15052.e4
216. Fodale, V., Tripodi, V. F., Penna, O., Famà, F., Squadrito, F., Mondello, E., & David, A. (2017). An update on anesthetics and impact on the brain. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1351539
217. Foley, C. M. (2017). Delirium. Routledge eBooks. https://doi.org/10.4324/9781315382760-62
218. Folkerth, R. D. (2021). Cerebral Cortical Migration Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.041
219. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
220. Forester, B. P., Marouf, F., Legesse, B., Okereke, O. I., & Blacker, D. (2021). Neurocognitive Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9780511846403.011
221. Forlenza, O. V. (2000). Transtornos depressivos na doença de Alzheimer: diagnóstico e tratamento. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462000000200010
222. Forrest, J., Willis, L., Holm, K., Kwon, M. S., Anderson, M. A., & Foreman, M. D. (2007). Recognizing quiet delirium.. PubMed. https://doi.org/10.1097/01.naj.0000265267.77070.0c
223. Francis, J. (1997). Delirium. Geriatric medicine. https://doi.org/10.1007/978-1-4757-2705-0_60
224. Franklin, M., Reeder, C. E., & Bramley, T. (2007). Current landscape of insomnia in managed care.. PubMed.
225. Freynhagen, R., & Bennett, M. (2009). Diagnosis and management of neuropathic pain. BMJ. https://doi.org/10.1136/bmj.b3002
226. Fukuda, J. S., Pires, M. M., Fukuda, T. G., & Oliveira‐Filho, J. (2016). Atualização sobre diagnóstico e tratamento das demências rapidamente progressivas com base na experiência do Serviço. Revista Científica Hospital Santa Izabel. https://doi.org/10.35753/rchsi.v3i2.475
227. Fulda, S. (2011). Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. The EPMA Journal. https://doi.org/10.1007/s13167-011-0096-8
228. Fuller, D. D., Mitchell, G. S., & Bavis, R. W. (2005). Respiratory Neuroplasticity: Respiratory Gases, Development, and Spinal Injury. CRC Press eBooks. https://doi.org/10.3109/9780203027103-13
229. Funder, K. S., Steinmetz, J., & Rasmussen, L. S. (2010). Methodological Issues of Postoperative Cognitive Dysfunction Research. Seminars in Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1177/1089253210371520
230. Galanter, M. (2014). Network Therapy for Substance Use Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg60
231. Galasko, D. (2019). Pharmacological Approaches To Behavioral Symptoms In Alzheimer’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429260353-28
232. Gale, R., & Rockwood, K. (2015). Dementia/Neurocognitive Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp379
233. Gankina, O. A. (2017). Neuropsychiatric disorders in dementia: mechanisms and treatment approach. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro20171176258-65
234. Garzola, G. C. Q. (2013). Role of nucleus accumbens glutamatergic plasticity in drug addiction. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s45963
235. Gaspersz, R., Nawijn, L., Lamers, F., & Penninx, B. W. (2017). Patients with anxious depression. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000376
236. Gasquoine, P. G. (2011). Cognitive impairment in common, noncentral nervous system medical conditions of adults and the elderly. Journal of Clinical and Experimental Neuropsychology. https://doi.org/10.1080/13803395.2010.536759
237. Gaytán, J. M. Q., Herrera, M. M., & Llanes, N. H. (2020). Ciclos circadianos desajustados en la relación del consumo de alcohol y depresión. Revista Internacional de Investigación en Adicciones. https://doi.org/10.28931/riiad.2020.2.07
238. Gałuszka, A. (2021). Znaczenie wsparcia dla funkcjonowania psychofizycznego osób opiekujących się bliskimi z chorobą Alzheimera. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2021.11.12.016
239. Gennaro, C., Laura, L., Marco, O., Sicuranza, R., Congedo, E., & Germano, D. C. (2017). Cognitive Dysfunction after Surgery: An Emergent Problem. Journal of Alzheimer’s Disease & Parkinsonism. https://doi.org/10.4172/2161-0460.1000304
240. George, O., Ahmed, S. H., & Gilpin, N. W. (2022). Are we compulsively chasing rainbows?. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01419-w
241. Gerc, K., & Makiełło-Jarzowa, G. (1998). [Psychological consequences of neurologic motor impairment from a developmental perspective].. PubMed.
242. Ghai, R., Sharma, C., Nagarajan, K., Mishra, S. K., Seth, D., Pandey, A., Kaushik, S., & Bhatt, P. (2022). epidemiological investigation of insomnia. International Journal of Health Sciences. https://doi.org/10.53730/ijhs.v6ns4.10162
243. Ghoneim, M. M., & Block, R. I. (2012). Clinical, methodological and theoretical issues in the assessment of cognition after anaesthesia and surgery. European Journal of Anaesthesiology. https://doi.org/10.1097/eja.0b013e328356bd6e
244. Ghosal, A., Bhattacharya, K., & Shobhana, A. (2021). Psychogenic anorexia and non-alcoholic Wernicke's encephalopathy. Journal of Acute Disease. https://doi.org/10.4103/2221-6189.307394
245. Giannakopoulos, P., Hock, C., Wettstein, A., Schüpbach, B., & Müller‐Spahn, F. (2000). [Diagnosis and therapy of behavior disorders in dementia].. PubMed.
246. Giazkoulidou, A., Messinis, L., & Nasios, G. (2019). Cognitive functions and social cognition in multiple sclerosis: An overview.. PubMed.
247. Glass, R. M. (1981). Cognitive Dysfunction and Imipramine in Outpatient Depressives. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1981.01780340100012
248. Gnädinger, L. C., Gagesch, M., & Schimmel, M. (2017). Bruxism in connection with neurocognitive disorders (in German)..
249. Goertchen, R., Wiedersberg, H., Goertchen, E., & Senitz, D. (1977). [Development of current problems regarding perinatal CNS lesions from a neuropathologic viewpoint].. PubMed.
250. Gold, B. G., Schnell, J. V., & Spencer, P. S. (2003). Neurotoxic Disorders. https://doi.org/10.1007/978-1-4757-4552-8_14
251. Golden, C. J., & Golden, Z. L. (2004). Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9780203336960-19
252. Goldstein, D. S. (2002). Dysautonomias: Clinical Disorders of the Autonomic Nervous System. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-137-9-200211050-00011
253. Gontkovsky, S. T. (2011). Acquired brain injury secondary to systemic sclerosis: A case report. Brain Injury. https://doi.org/10.3109/02699052.2011.607784
254. Gorre, V. N., Upadhyay, D. K., Shrivastava, B., & Kumar, K. R. (2023). A REVIEW ON COGNITIVE IMPAIRMENT AND QUALITY OF LIFE, MEDICATION ADHERENCE AND THE PRESCRIPTION PATTERN FOR SCHIZOPHRENIA. European Chemical Bulletin. https://doi.org/10.48047/ecb/2023.12.1.327
255. Gounard, B. R., & Hulicka, I. M. (1977). MAXIMIZING LEARNING EFFICIENCY IN LATER ADULTHOOD: A COGNITIVE PROBLEM‐SOLVING APPROACH. Educational Gerontology. https://doi.org/10.1080/0360127770020405
256. Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. A. (2011). 17 Neurodegenerative Disorders. Georg Thieme Verlag eBooks. https://doi.org/10.1055/b-0034-75424
257. Gray, J., Nagel, J. A., Amrein, R., Marini, G., & Senin, U. (1994). Therapeutic Efficacy of Nootropic Drugs in Alzheimer’s Disease and Age Related Cognitive Dysfunction. Birkhäuser Boston eBooks. https://doi.org/10.1007/978-1-4615-8149-9_46
258. Greden, J. F. (2003). Physical symptoms of depression: unmet needs.. PubMed.
259. Greenfield, M. J., Fobian, A. D., Fargason, R. E., & Birur, B. (2024). Optimizing outcomes when treating functional neurological disorder in acute care settings: case reports depicting the value of diagnostic precision and timely and appropriate psychological interventions using an interdisciplinary framework. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1288828
260. Greetfeld, M., Cuntz, U., & Voderholzer, U. (2011). Pharmakotherapie von Anorexia nervosa und Bulimia nervosa: State of the Art. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0031-1281845
261. Groep, G.-V. D., & De, K. (2019). Identification of neural and non-neural contributors to joint stiffness in upper motor neuron disease.
262. Grégoire, A., & Spoors, J. (2019). ECT in Pregnancy and Postnatally. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623175.008
263. Guerdjikova, A. I., McElroy, S. L., Barger, S. D., Barth, J., Farrelly, S., & Brohan, E. (2019). Recent Advances in Depressive Disorder.
264. Guerrini, R., & Falchi, M. (2011). Dravet syndrome and <i>SCN1A</i> gene mutation related‐epilepsies: cognitive impairment and its determinants. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2011.03966.x
265. Gupta, S., Laddha, A., Chaturvedi, P., Chaturvedi, N., Mishra, A., & Raghvendra, R. (2011). Trends and strategy towards therapies for status epilepticus: A decisive review. International Journal of Pharmaceutical Sciences Review and Research.
266. Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020). The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320967183
267. Guzmán, J., & Salinas, R. (2012). Encefalomielitis aguda diseminada y colitis ulcerosa: descripción de un caso clínico. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272012000100007
268. Gynther, B., Calford, M. B., & Sah, P. (1998). Neuroplasticity and psychiatry. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1046/j.1440-1614.1998.00381.x
269. Gynther, B., Calford, M. B., & Sah, P. (1998). Neuroplasticity and Psychiatry. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048679809062718
270. Gélinas, C., Klein, K., Naidech, A., & Skrobik, Y. (2013). Pain, Sedation, and Delirium Management in the Neurocritically Ill: Lessons Learned from Recent Research. Seminars in Respiratory and Critical Care Medicine. https://doi.org/10.1055/s-0033-1342986
271. Gómez‐Tortosa, E., Rigual, R., Prieto-Jurczynska, C., Mahíllo, I., Guerrero, R., Pérez‐Pérez, J., & Sainz, M. J. (2015). Behavioral Evolution of Progressive Semantic Aphasia in Comparison with Nonfluent Aphasia. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000439521
272. Günal, D. İ., Nurichalichi, K., Tuncer, N., Bekiroğlu, N., & Aktan, S. (2002). The Clinical Profile of Nonmotor Fluctuations in Parkinson's Disease Patients. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100001736
273. Hainline, B., Gurin, L., & Torres, D. M. (2019). Anxiety Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0016
274. Hainline, B., Gurin, L., & Torres, D. M. (2019). Chronic Traumatic Encephalopathy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0036
275. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
276. Hainline, B., Gurin, L., & Torres, D. M. (2019). Depression Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0015
277. Haken, R. V., & Hansen, H.-C. (2019). [Detection of delirium in three steps - From Screening to Verification to Etiology].. DMW - Deutsche Medizinische Wochenschrift.
278. Haken, R. V., & Hansen, H.-C. (2019). Delir erkennen in 3 Schritten. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/a-0767-9764
279. Halbauer, J. D., Ashford, J. W., Zeitzer, J. M., Adamson, M. M., Lew, H. L., & Yesavage, J. A. (2009). Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. The Journal of Rehabilitation Research and Development. https://doi.org/10.1682/jrrd.2008.08.0119
280. Halvorsen, H. T., Hammer, S. K., Nystrøm, V., & Leonardsen, A. L. (2019). Delirium hos intuberte intensivpasienter. iNSPIRA. https://doi.org/10.23865/inspira.v14.2784
281. Han, I.-W., & Seo, S. (1997). Memory Impairment in Dementing Patients. Sleep Medicine and Psychophysiology.
282. Harris, R. D., Taylor, O. A., Raghubar, K. P., Gonzalez, M. M., Zobeck, M., Gramatges, M. M., Rabin, K. R., Scheurer, M. E., & Brown, A. L. (2024). Episodes of acute methotrexate‐related neurotoxicity linked to compromised long‐term neurocognitive function. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31169
283. Hashimoto, K. (2019). Non-attendance at School of Children with Neurocognitive Disorder after Brain Injury. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.56.463
284. Haslam, R. H. A. (1997). Nonfebrile Seizures. Pediatrics in Review. https://doi.org/10.1542/pir.18.2.39
285. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
286. Hayes, C., & Molloy, A. R. (1997). Neuropathic Pain in the Perioperative Period. International Anesthesiology Clinics. https://doi.org/10.1097/00004311-199703520-00006
287. Heinz, A. (2017). Learning Mechanisms in Addictive Disorders. The MIT Press eBooks. https://doi.org/10.7551/mitpress/9780262036894.003.0008
288. Helbig, K. L., & Goldberg, E. M. (2021). SCN3A- Related Neurodevelopmental Disorder.
289. Helmstaedter, C., Tailby, C., & Witt, J. (2024). Neuropsychology of late-onset epilepsies. Seizure. https://doi.org/10.1016/j.seizure.2024.03.010
290. Hemmeter, U.-M., Thum, N., Hemmeter-Spernal, U., Pd, M., Psychiatrische, K., & St, D. (2011). Schlafstörungen im Alter. Schweizer Archiv für Neurologie und Psychiatrie. https://doi.org/10.4414/sanp.2011.02254
291. Hernandez, K. S. (2019). Relación etiológica de convulsiones neonatales con el desarrollo de epilepsia a 36 meses. Seguimiento en el INP.
292. Hernández, O. M. O. M., & Morales, X. (2018). Fiesta neuronal: estado epiléptico en pediatría. Anales médicos (México, D.F.).
293. Herreras, E. B., & Gutiérrez, G. M. (2008). Adicciones y funcionamiento ejecutivo. Polibea.
294. Herreras, E. B., & Gutiérrez, G. M. (2008). Adicciones y funcionamiento ejecutivo. Psicología y Psicopedagogía.
295. Hickie, I. B., Cuijpers, P., Scott, E., & Iorfino, F. (2024). Is it time to abandon the concept of treatment-resistant depression?. Research Directions Depression. https://doi.org/10.1017/dep.2024.2
296. Hill, P. (2006). Adjustment disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543807.008
297. Hocker, S. E. (2015). Intoxications and Nontraumatic Neurologic Injury. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0093
298. Hollon, S. D. (2015). The efficacy and acceptability of psychological interventions for depression: where we are now and where we are going. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796015000748
299. Hopkins, R. O., & Brett, S. J. (2005). Chronic neurocognitive effects of critical illness. Current Opinion in Critical Care. https://doi.org/10.1097/01.ccx.0000166399.88635.a5
300. Hopkins, R. O., & Jackson, J. C. (2016). Neurocognitive impairment after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199600830.003.0382
301. Hotton, G., & Clough, C. (2004). Other Drug-Induced Movement Disorders. CRC Press eBooks. https://doi.org/10.1201/9780203913611-20
302. Howard, R., Tan, S. V., & Z’Graggen, W. J. (2008). Weakness on the intensive care unit. Practical Neurology. https://doi.org/10.1136/jnnp.2008.157263
303. Hu, W., Liu, S., Gan, J., Li, Z., Shi, Z., Li, Y., & Ji, Y. (2019). Neurofibriilary tangle-predominant dementia. https://doi.org/10.3760/cma.j.issn.0254-9026.2019.11.030
304. Huecker, M., Bhutta, B. S., Dominique, E., & Bossuah, K. A. (2021). Adrenal Insufficiency (Nursing).
305. Hulse, G. K., Lautenschlager, N. T., Tait, R. J., & Almeida, O. P. (2005). Dementia associated with alcohol and other drug use. International Psychogeriatrics. https://doi.org/10.1017/s1041610205001985
306. Hutton, J. L., Hunter, M. S., Jarrett, S., & Zoysa, N. D. (2014). CBT with People with Long‐Term Medical Conditions. https://doi.org/10.1002/9781394266487.ch11
307. Ibach, B. (2007). Demenzerkrankungen - Behandlung von Verhaltensstörungen mit Neuroleptika. psychoneuro. https://doi.org/10.1055/s-2007-985199
308. Ibrahim, I. R., & Amar, K. (2007). Mild cognitive impairment. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2007.68.10.27322
309. Ibáñez, A. G., Bolumburu, E. U., & Torres, C. V. (2012). Estado epiléptico no convulsivo en el siglo XXI: clínica, diagnóstico, tratamiento y pronóstico. Revista de Neurología. https://doi.org/10.33588/rn.5402.2011250
310. Ida, M., & Kawaguchi, M. (2014). [Postoperative cognitive dysfunction after non-cardiac surgery].. PubMed.
311. Iorga, M., Stârcea, I. M., Munteanu, M., & Sztankovszky, L.-Z. (2014). PSYCHOLOGICAL AND SOCIAL PROBLEMS OF CHILDREN WITH CHRONIC KIDNEY DISEASE.
312. Iqbal, R. K. (2019). Delirium: An Acute Confusional State. Annals of Advanced Biomedical Sciences. https://doi.org/10.23880/aabsc-16000132
313. Irfana, L. (2018). NEUROPATI OPTIK TOKSIK AKIBAT ETAMBUTOL. PROCEEDING UMSURABAYA.
314. Ivlieva, N. Y. (2011). [Neurobiology of addictive behavior].. PubMed.
315. Jahraus, J. (2018). Medical Complications of Eating Disorders. Psychiatric Annals. https://doi.org/10.3928/00485713-20180912-04
316. Jain, A. A. (2021). Narcolepsy: A Chronic Neurological Disorder - A Review. Bioscience Biotechnology Research Communications. https://doi.org/10.21786/bbrc/14.6.61
317. Jain, K. K. (2019). Introduction. Springer protocols handbooks/Springer protocols. https://doi.org/10.1007/978-1-4939-9465-6_1
318. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
319. Janelidze, M., & Botchorishvili, N. (2018). Mild Cognitive Impairment. InTech eBooks. https://doi.org/10.5772/intechopen.75509
320. Janicak, P. G. (2014). Pharmacological Treatment of Psychosis. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg11
321. Janjua, T., Agrawal, A., Picón‐Jaimes, Y. A., Lozada-Martínez, I. D., Perez-Velasquez, B. V., Mendoza-Ortiz, A., & Moscote‐Salazar, L. R. (2022). Therapeutic Momentum: Scenarios in Patients with Neurotrauma. Journal of Neurointensive Care. https://doi.org/10.32587/jnic.2021.00430
322. Jaqua, E., Hanna, M., Labib, W., Moore, C., & Matossian, V. (2022). Common Sleep Disorders Affecting Older Adults. The Permanente Journal. https://doi.org/10.7812/tpp/22.114
323. Jenkins, T. M., Brockington, A., & Shaw, P. J. (2020). The motor neuron diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0604
324. Jennum, P., Martiny, K., & Bech, P. (2009). [Insomnia].. PubMed.
325. Jensen, T. S. (2002). An improved understanding of neuropathic pain. European Journal of Pain. https://doi.org/10.1016/s1090-3801(02)90002-9
326. Jiménez, D. E. A. (2020). El trastorno por consumo de alcohol como producto del conflicto intrapsíquico. Revista Torreón Universitario. https://doi.org/10.5377/torreon.v9i26.10261
327. Jm, V. G., Hj, G., Rj, V., & Af, C. (1998). [Cognitive and psychotic effects after cessation of chronic cannabis use].. PubMed.
328. Johansson, B., Andréll, P., Mannheimer, C., & Rönnbäck, L. (2022). [Mental fatigue - possible explanations, diagnostic methods and possible treatments].. PubMed.
329. Johnson, E. L., & Kaplan, P. W. (2020). Status Epilepticus: Definition, Classification, Pathophysiology, and Epidemiology. Seminars in Neurology. https://doi.org/10.1055/s-0040-1718722
330. Jones, K. C., Han, J. Y., & Shah, A. A. (2016). Cognitive Continuum: Areas of Controversy with Cognitive Enhancers. Psychiatric Annals. https://doi.org/10.3928/00485713-20151221-02
331. Jordan, K. G. (1999). Nonconvulsive Status Epilepticus in Acute Brain Injury. Journal of Clinical Neurophysiology. https://doi.org/10.1097/00004691-199907000-00005
332. Jun, L., Huang, K., Zhu, B., Zhou, B., Harb, A. K. A., Liu, L., & Wu, X. (2021). Neuropsychological Tests in Post-operative Cognitive Dysfunction: Methods and Applications. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.684307
333. Kabel, A. M., & Maghrabi, I. A. (2014). Sleep and its disorders. El Mednifico Journal. https://doi.org/10.18035/emj.v2i4.255
334. Kalimo, H., & Smith, M. (1986). Structural Aspects of Ischemic Brain Damage. https://doi.org/10.1007/978-3-7091-8859-0_35
335. Kamenskiy, I., Kaymovskiy, I. L., Gersamiya, A. G., & Vavilina, I. (2017). Cognitive impairment. The effects of seizures?. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro20171179250-54
336. Kanellopoulos, D., & Vallejo, P. S.-B. (2019). Substance Related Cognitive Dysfunction in Aging. Clinical handbooks in neuropsychology. https://doi.org/10.1007/978-3-319-93497-6_19
337. Kapczinski, F. (2015). Biomarkers of Neuroprogression in Bipolar Disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31830-7
338. Kaplan, P. W. (1999). Assessing the Outcomes in Patients With Nonconvulsive Status Epilepticus: Nonconvulsive Status Epilepticus Is Underdiagnosed, Potentially Overtreated, and Confounded by Comorbidity. Journal of Clinical Neurophysiology. https://doi.org/10.1097/00004691-199907000-00006
339. Kapp, M. B. (2016). Legal issues in dementia. CRC Press eBooks. https://doi.org/10.3109/9781420020250-13
340. Kara, W. A., Bakari, K. H., Mayala, H., Shao, B., & Mao, J. (2017). Neurocognitive Effects of Electroconvulsive Therapy in Psychiatric Disorders, Mechanism of Action And its Prevention: Review Article. IOSR Journal of Dental and Medical Sciences. https://doi.org/10.9790/0853-1604078792
341. Karbowski, K. (1990). [Rudimentary psychomotor seizures and their differential diagnosis].. PubMed.
342. Karimzadeh, P. (2015). Approach to neurometabolic diseases from a pediatric neurological point of view.. PubMed.
343. Kariya, S. K., Fokmare, P. S., Harjpal, P. L., & Samal, S. (2022). Positive impact of vestibular training along with neurodevelopmental therapy to improve overall quality of life of a cerebral palsy baby: A case report. Medical Science. https://doi.org/10.54905/disssi/v26i124/ms206e2220
344. Karri, J., Chien, G. C. C., & Abd‐Elsayed, A. (2019). Nerve Entrapments of the Lower Extremity. Pain. https://doi.org/10.1007/978-3-319-99124-5_166
345. Karthikeyan, A., John, S. K., Subramaniam, K., Vinitha, U., & Kumar, S. (2016). Nutraceutical approach for neurocognitive disease management with antioxidant active molecules. Indian journal of science.
346. Katz, I. R., & DiFilippo, S. (1997). Neuropsychiatric Aspects of Failure to Thrive in Late Life. Clinics in Geriatric Medicine. https://doi.org/10.1016/s0749-0690(18)30140-x
347. Katzman, M. A. (2021). The Diagnosis of Major Depressive Disorder is based on the Person's Reported Experiences and a Mental Status Examination. Journal of Aging and Geriatric Medicine.
348. Kavanaugh, B. C., Dupont-Frechette, J. A., Jerskey, B. A., & Holler, K. (2016). Neurocognitive deficits in children and adolescents following maltreatment: Neurodevelopmental consequences and neuropsychological implications of traumatic stress. Applied Neuropsychology Child. https://doi.org/10.1080/21622965.2015.1079712
349. Kaye, W. H., Wierenga, C. E., Bailer, U. F., Simmons, A. N., & Bischoff‐Grethe, A. (2014). Nothing Tastes as Good as Skinny Feels: the Neurobiology of Anorexia Nervosa. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.120413
350. Keller, M. B., Hirschfeld, R. M. A., Demyttenaere, K., & Baldwin, D. S. (2002). Optimizing outcomes in depression: focus on antidepressant compliance. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200211000-00001
351. Kellett, J. M. (1993). Long term care on the NHS: a vanishing prospect.. BMJ. https://doi.org/10.1136/bmj.306.6881.846
352. Kempster, P., Williams, D. R., Selikhova, M., Holton, J., Révész, T., & Lees, A. J. (2007). Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain. https://doi.org/10.1093/brain/awm142
353. Kennedy, M. (2018). Delirium In The Emergency Department: Diagnosis, Evaluation, And Management. DeckerMed Medicine. https://doi.org/10.2310/im.4709
354. Kennedy, M. (2018). Delirium In The Emergency Department: Diagnosis, Evaluation, And Management. https://doi.org/10.2310/7ccsp.4709
355. Kennedy, M. (2018). Delirium In The Emergency Department: Diagnosis, Evaluation, And Management. https://doi.org/10.2310/em.4709
356. Kennedy, M. (2018). Delirium In The Emergency Department: Diagnosis, Evaluation, And Management. https://doi.org/10.2310/neuro.4709
357. Kennedy, M. (2018). Delirium In The Emergency Department: Diagnosis, Evaluation, And Management. https://doi.org/10.2310/psych.4709
358. Kerchner, G. A., & Rosenbloom, M. (2014). Frontotemporal Neurocognitive Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg65
359. Kessels, R. P. C., & Savage, G. (2015). Amnestic Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp060
360. Khan, A. Y., Kalia, R., Ide, G. D., & Ghavami, M. (2017). What Are Realistic Treatment Goals? Lingering Symptoms Require You to Evaluate Pharmacotherapy and Offer Psychosocial Interventions. Current psychiatry.
361. Khot, S., & Tirschwell, D. (2006). Long-Term Neurological Complications after Hypoxic-Ischemic Encephalopathy. Seminars in Neurology. https://doi.org/10.1055/s-2006-948323
362. Kim, D. (2020). Prolonged Disorders of Consciousness. Journal of the Korean Neurological Association. https://doi.org/10.17340/jkna.2020.1.2
363. Kim, H. K. (2018). Myoclonic Status Epilepticus of Unknown Etiology in an Elderly Patient. Journal of Clinical Neurology. https://doi.org/10.3988/jcn.2018.14.1.100
364. Kimball, A. B., & Grossman, S. A. (2017). Syncope And Related Paroxysmal Spells.
365. King, A. P., & Fresco, D. M. (2018). A neurobehavioral account for decentering as the salve for the distressed mind. https://doi.org/10.31231/osf.io/8d6wu
366. Kirilly, E., Gonda, X., Juhász, G., & Bagdy, G. (2013). Nem pszichiátriai gyógyszerek szorongást és depressziót kiváltó mellékhatásai | Anxiogenic and depressogenic side-effects of non-psychiatric drugs.
367. Kirmani, B., Au, K., Ayari, L., John, M., Shetty, P. A., & DeLorenzo, R. J. (2021). Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management. Aging and Disease. https://doi.org/10.14336/ad.2021.0302
368. Kitching, D. (2015). Depression in dementia. Australian Prescriber. https://doi.org/10.18773/austprescr.2015.071
369. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2007.9.2/hkleber
370. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options.. PubMed.
371. Klein, A., Moskau, S., Klockgether, T., & Linnebank, M. (2006). Transient global amnesia like episode in a dialysis patient with severe hyperhomocysteinaemia. Aktuelle Neurologie. https://doi.org/10.1055/s-2006-953442
372. Kleinknecht, R. A., & Goldstein, S. G. (1972). Neuropsychological Deficits Associated with Alcoholism; A Review and Discussion. Quarterly Journal of Studies on Alcohol. https://doi.org/10.15288/qjsa.1972.33.999
373. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
374. Knight, M. J., Mills, N., & Baune, B. T. (2019). Contemporary methods of improving cognitive dysfunction in clinical depression. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1610395
375. Knupp, K. G., & Wirrell, E. (2014). Progressive myoclonic epilepsies. Neurology. https://doi.org/10.1212/wnl.0000000000000091
376. Kocabaşoğlu, N., Karaçetin, G., Bayar, R., & Demir, T. (2012). A Review of the Etiology Delirium. InTech eBooks. https://doi.org/10.5772/32411
377. Kojima, T., & Akishita, M. (2016). [Drug-induced dementia].. PubMed.
378. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4.473
379. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4_part_2.473
380. Komoltsev, I., & Gulyaeva, N. V. (2022). Brain Trauma, Glucocorticoids and Neuroinflammation: Dangerous Liaisons for the Hippocampus. Biomedicines. https://doi.org/10.3390/biomedicines10051139
381. Koob, G. F. (2013). Addiction is a Reward Deficit and Stress Surfeit Disorder. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2013.00072
382. Koob, G. F. (2013). Neurocircuitry of Addiction: A brain reward deficit, stress surfeit and executive function disorder. Suchttherapie. https://doi.org/10.1055/s-0033-1351398
383. Koob, G. F., & Moal, M. L. (2007). Addiction and the Brain Antireward System. Annual Review of Psychology. https://doi.org/10.1146/annurev.psych.59.103006.093548
384. Koob, G. F., & Zorrilla, E. P. (2010). Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor.. PubMed.
385. Kopach, O., & Pivneva, T. (2018). Cell-based therapies for neural replacement strategies in stroke-related neurodegeneration: neurophysiological insights into stem progenitor cell neurogenesis within a host environment. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.235224
386. Korn‐Lubetzki, I., Steiner‐Birmanns, B., Galperin, I., Benasouli, Y., & Steiner, I. (2007). NONCONVULSIVE STATUS EPILEPTICUS IN OLDER PEOPLE: A DIAGNOSTIC CHALLENGE AND A TREATABLE CONDITION. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2007.01284.x
387. Korolev, A., & Nikiforov, M. V. (2024). Nutritional status and nutritional support of patients with chronic disorders of consciousness at the stage of medical rehabilitation. Problems of Nutrition. https://doi.org/10.33029/0042-8833-2024-93-3-50-58
388. Korsnes, M. S., & Ulstein, I. (2014). Cognitive Effects of Late Life Depression: Review of Neuropsychological Findings. Journal of Behavioral and Brain Science. https://doi.org/10.4236/jbbs.2014.43018
389. Kosivtsova, O. V., Platov, M. P., & Kochetov, S. A. (2020). Cognitive impairment and distal polyneuropathy in a patient with diabetes mellitus in neurological outpatient practice. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2020-3-111-116
390. Kozaki, K. (2018). VI. Age-dependent Cognitive Impairment and Dementia. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.107.2461
391. Krinsky‐McHale, S. J., & Silverman, W. (2013). Dementia and mild cognitive impairment in adults with intellectual disability: Issues of diagnosis. Developmental Disabilities Research Reviews. https://doi.org/10.1002/ddrr.1126
392. Kristan, A. M., & Santos, E. J. (2022). Am I losing my mind?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197521670.003.0007
393. Kroeger, D., & Vetrivelan, R. (2023). To sleep or not to sleep – Effects on memory in normal aging and disease. Aging Brain. https://doi.org/10.1016/j.nbas.2023.100068
394. Krombach, J., Hörmann, S., Huber, C., Hölzle, P., & Förstl, H. (2021). Alt und depressiv oder dement? – Pseudodepression vs. Pseudodemenz. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/a-1180-2417
395. Krystal, A. D. (2007). The Morbidity of Insomnia. CNS Spectrums. https://doi.org/10.1017/s1092852900026110
396. Kukla, U., Łabuzek, K., Chronowska, J., Krzystanek, M., & Okopień, B. (2015). [Mental disorders in digestive system diseases - internist's and psychiatrist's insight].. PubMed.
397. Kulagina, I. I., & Puskaeva, T. D. (1990). Cognitive Activity and Its Determinants in Delayed Mental Development. Soviet Education. https://doi.org/10.2753/res1060-9393321058
398. Kusper, T. M., Candido, K. D., & Knežević, N. N. (2019). Neurolysis. Pain. https://doi.org/10.1007/978-3-319-99124-5_186
399. Kutoku, Y., & Mihara, M. (2018). Drug Treatments of Dementia. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.55.643
400. Kügler, J., Schrader, A., Spatz, R., & Ross, A. (1977). [Diagnostic value of the EEG. Neurologic diagnosis today].. PubMed.
401. Lacassie, H. J., & Muir, H. A. (2008). Chronic pain in pregnancy. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544552.013
402. Lado, F. A., Laureta, E., & Moshé, S. L. (2002). Seizure‐induced hippocampal damage in the mature and immature brain. Epileptic Disorders. https://doi.org/10.1684/j.1950-6945.2002.tb00479.x
403. Lago, A. L., & García, A. (2006). Alcohol y sistema nervioso central. Adicciones.
404. Lam, R. W. (2018). Associated clinical features. Depression. https://doi.org/10.1093/med/9780198804147.003.0005
405. Lambert, M., Schimmelmann, B. G., Karow, A., & Naber, D. (2003). Subjective Well-being and Initial Dysphoric Reaction under Antipsychotic Drugs - Concepts, Measurement and Clinical Relevance. Pharmacopsychiatry. https://doi.org/10.1055/s-2003-45128
406. Lamont, P. J. (2004). cognitive decline in a young adult with pre-existent developmental delay - what the adult neurologist needs to know. Practical Neurology. https://doi.org/10.1111/j.1474-7766.2004.02-206.x
407. Lance, J. W. (1988). Association of lower motor neuron disorders with fasciculation, neuromyotonia and myoclonus.. PubMed.
408. Lanièpce, A., Cabé, N., André, C., Bertran, F., Boudehent, C., Lahbairi, N., Maillard, A., Mary, A., Segobin, S., Vabret, F., Rauchs, G., & Pitel, A. (2020). The effect of alcohol withdrawal syndrome severity on sleep, brain and cognition. Brain Communications. https://doi.org/10.1093/braincomms/fcaa123
409. Lara, E. (2017). Deterioro cognitivo leve y reserva cognitiva en una muestra representativa de la población española.
410. Lara-Plaza, O., Solís‐Navarro, L., Rivera‐Lillo, G., & Torres‐Castro, R. (2022). Cognitive and motor performance effects of non-invasive brain stimulation in patients with traumatic brain injury: A meta-analysis of randomised controlled trials. https://doi.org/10.37766/inplasy2022.4.0067
411. Lauter, V., & Kurz, A. (2001). Clinical Assessment of the Dementias. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_67
412. Lee, Y. L., Wong, J., & Ng, S. Y. (2022). Delirium in patients following general anaesthesia. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.202228
413. Leggett, A., Assari, S., Burgard, S., & Zivin, K. (2015). BLACK-WHITE DIFFERENCES IN THE LONGITUDINAL ASSOCIATIONS BETWEEN DEPRESSIVE. The Gerontologist. https://doi.org/10.1093/geront/gnv278.05
414. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
415. Lewis, S., Tarrier, N., & Drake, R. (2005). Integrating non-drug treatments in early schizophrenia. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.187.48.s65
416. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
417. Liberalesso, P. B. N. (2018). Status epilepticus. Diagnosis and treatment. Residência Pediátrica. https://doi.org/10.25060/residpediatr-2018.v8s1-06
418. Lieberman, J. A. (2007). Therapeutics for the Treatment of Insomnia. CNS Spectrums. https://doi.org/10.1017/s1092852900026122
419. Lieberman, J. A., Buckley, P., & Perkins, D. O. (2007). Neuroprotection: A New Strategy in the Treatment of Schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852900026328
420. Lieberman, J., Malaspina, D., & Jarskog, L. F. (2006). Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.. CNS Spectrums.
421. Lieblich, S. E. (2015). Delayed Awakening from Anesthesia. https://doi.org/10.1002/9781119053231.ch40
422. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
423. Limandri, B. J. (2018). Insomnia: Will Medication Bring Rest?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20180619-03
424. Lin, J. C., Mueller, C., Campbell, K. A., Thannickal, H. H., Daredia, A., Sheriff, S., Maudsley, A. A., Brunner, R., & Younger, J. (2021). Investigating whole‐brain metabolite abnormalities in the chronic stages of moderate or severe traumatic brain injury. PM&R. https://doi.org/10.1002/pmrj.12623
425. Lindemann, A., Antille, V., & Clarke, S. (2011). [Cognitive impairment in alcohol addiction].. Revue Médicale Suisse.
426. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
427. Liu, H., Du, W., Wang, L., & Su, F. (2010). Early neurological deterioration in patients with acute ischemic stroke. Chinese Journal of Neuromedicine. https://doi.org/10.3760/cma.j.issn.1671-8925.2010.03.026
428. Lléo, A., & Blesa, R. (2011). Clinical course of Alzheimer’s disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199569854.003.0002
429. Lockhart, S., Sawa, A., & Niwa, M. (2018). Developmental trajectories of brain maturation and behavior: Relevance to major mental illnesses. Journal of Pharmacological Sciences. https://doi.org/10.1016/j.jphs.2018.04.008
430. Loitman, J. E., & Deshields, T. L. (2010). Psychiatric Palliative Care Issues. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-590-3_4
431. Love, M., & Geldmacher, D. (2018). Alzheimer’s Disease. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy20
432. Luisetto, M. (2018). Mindset kinetics and Some Depression Status: A New Quantitative Model Under Biochemical-Toxicology Approach?. Journal of pharmacology & clinical research. https://doi.org/10.19080/jpcr.2018.05.555680
433. Lyketsos, C. G. (2012). F1‐01‐02: Tackling overlap of neuropsychiatric symptoms in Alzheimer's and other dementias: Toward a unified approach to evaluation and treatment. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2012.05.191
434. Lyketsos, C. G., López, O. L., Jones, B. N., Fitzpatrick, A. L., Breitner, J. C., & DeKosky, S. T. (2002). Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment. JAMA. https://doi.org/10.1001/jama.288.12.1475
435. Lévy, R., & Pillon, B. (2006). [Cognitive disorders in Parkinson's disease without dementia].. PubMed.
436. MacDonald, J. T. (1988). Childhood seizures. Postgraduate Medicine. https://doi.org/10.1080/00325481.1988.11700221
437. Macovei, A. L., Dobrin, I., Chiriță, V., Burlui, A., Dobrin, P.-R., & Rezuş, E. (2019). Chronic fatigue and psychiatric comorbidities in patients with rheumatic disorders. Bulletin of Integrative Psychiatry. https://doi.org/10.36219/bpi.2019.03.08
438. Maddocks, I., Brew, B. J., Waddy, H., & Williams, I. (2005). Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545016.020
439. Maddocks, I., Brew, B. J., Waddy, H., & Williams, I. (2005). Problems with muscles and movement. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545016.009
440. Maddocks, I., Brew, B. J., Waddy, H., & Williams, I. (2005). Proxy decision-making. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545016.030
441. Madrigal, J. G. T. (2012). Status epiléptico en emergencias: manejo tradicional y tendencia actual. Revista Médica de Costa Rica y Centroamérica.
442. Maes, M., Altufaili, M. F., Alhaideri, A. F., Moustafa, S. R., Stoyanova, K., Niu, M., Zhou, B., Li, J., & Al‐Hakeim, H. K. (2024). The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/0115680266320808240709061445
443. Magalhaes, É., Polito, A., Polito, A., & Sharshar, T. (2014). Sepsis-Associated Encephalopathy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199653461.003.0032
444. Magistris, M., & Soichot, P. (2004). [Neuropathy versus neuronopathy: distinctive features].. PubMed.
445. Malaiyandi, D., & Živković, S. (2018). Neuromuscular Conditions. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199375349.003.0013
446. Malan, L., & Dlamini, N. (2017). Clinical practice guidelines for insomnia disorder. South African Family Practice. https://doi.org/10.4102/safp.v59i3.4691
447. Maletic, V., & DeMuri, B. (2016). Chronic Pain and Depression: Understanding 2 Culprits in Common: Does a Shared Pathophysiology Hold the Key to Managing These Conditions When They Coexist?. Current psychiatry.
448. Mameli, M. (2009). Controlling the persistence of drug-evoked plasticity in the mesolimbic dopamine system. https://doi.org/10.13097/archive-ouverte/unige:2138
449. Manning, K. J., & Steffens, D. C. (2018). State of the Science of Neural Systems in Late‐Life Depression: Impact on Clinical Presentation and Treatment Outcome. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.15353
450. Manschreck, T. C. (1996). Delusional disorder: the recognition and management of paranoia.. PubMed.
451. Marazzi, C., Scoditti, U., Ticinesi, A., Nouvenne, A., Pigna, F., Guida, L., Morelli, I., Borghi, L., & Meschi, T. (1996). Transient global amnesia. Neurocase. https://doi.org/10.1080/13554799608402389
452. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
453. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
454. Marino, S., Ciurleo, R., Baglieri, A., Corallo, F., De, R., De, S., Guerrera, S., Timpano, F., Bramanti, P., & Nicola, S. D. (2012). Neuroimaging and Outcome Assessment in Vegetative and Minimally Conscious State. InTech eBooks. https://doi.org/10.5772/23003
455. Marques, S., Vauclair, C., Rodrigues, R. B., Mendonça, J., Gerardo, F., & Cunha, F. O. (2015). NEGATIVE SELF-PERCEPTIONS OF AGING PREDICT DECLINES IN MEMORY PERFORMANCE OVER TIME. The Gerontologist. https://doi.org/10.1093/geront/gnv379.04
456. Martinez, J. D. (2020). El paciente con cefalea por uso excesivo de medicamentos en urgencias. Acta neurológica colombiana. https://doi.org/10.22379/24224022314
457. Martínez‐Arán, A., Bonnín, C. D. M., Torrent, C., Solé, B., Torres, I., & Jiménez, E. (2015). Cognition and illness progression in bipolar disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198709992.003.0006
458. Martínez‐Castrillo, J. C., Vela, L., Val, J. D., & Alonso‐Cánovas, A. (2011). Nonmotor Disorders and Their Correlation With Dopamine. The Neurologist. https://doi.org/10.1097/nrl.0b013e318239669f
459. Masel, B. E., & DeWitt, D. S. (2010). Traumatic Brain Injury: A Disease Process, Not an Event. Journal of Neurotrauma. https://doi.org/10.1089/neu.2010.1358
460. Masse, C., Chopard, G., Bennabi, D., Haffen, É., & Vandel, P. (2021). Cognitive functions in late life depression. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2021.0939
461. Mateen, Y., Lally, J., & Bokhari, S. Q. (2022). Chronic, Unipolar, Treatment-Resistant Mania: A Case Report and Literature Review. BJPsych Open. https://doi.org/10.1192/bjo.2022.363
462. Matta, S. M. D., Moreira, J. M., Kümmer, A., Barbosa, I. G., Teixeira, A. L., & Silva, A. C. S. E. (2014). Cognitive alterations in chronic kidney disease: an update. Brazilian Journal of Nephrology. https://doi.org/10.5935/0101-2800.20140035
463. Matuszewska, M., Brzozowska, M., Wardal, W., Furlepa, N., Rzenno, R., Wojciechowska, K., Wicha, K., Sidz, N., Tomaszewska, M., & Jedlikowska, W. (2025). The Long-Term Effects of Alcohol on the Central Nervous System: Mechanisms, Cognitive Decline, and Associated Disorders. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2025.80.59611
464. Mc, M.-S. (1993). [Post-traumatic stress syndrome in children].. PubMed.
465. McEvoy, J. P., Asuzu, K., Bradford, D. W., Freudenreich, O., & Moyer, K. (2020). Treatment and management of patients with schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0065
466. McIntyre, R. S., Lee, Y., Carmona, N. E., Subramaniapillai, M., Danielle, S., Lee, J., Lee, Y., Alageel, A., Rodrigues, N. B., Park, C., Ragguett, R., Rosenblat, J. D., Almatham, F., Pan, Z., Rong, C., & Mansur, R. B. (2018). Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder. Harvard Review of Psychiatry. https://doi.org/10.1097/hrp.0000000000000171
467. McQuay, H. J., & Wiffen, P. J. (2010). Antidepressants and antiepileptics for neuropathic pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199563678.003.0011
468. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
469. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
470. Medjkane, F., Bohet, M., Ister, M., Cohen, D., Parenti, A., Janati, M., Mention, K., Dobbelaere, D., & Jardri, R. (2021). Onset of psychiatric signs and impaired neurocognitive domains in inherited metabolic disorders: A case series. JIMD Reports. https://doi.org/10.1002/jmd2.12133
471. Medrano‐Martínez, P., Platón, M., & Peraita‐Adrados, R. (2018). Alteraciones neuropsicológicas en la narcolepsia con cataplejía: una revisión. Revista de Neurología. https://doi.org/10.33588/rn.6603.2017448
472. Meekes, J., & Jennekens‐Schinkel, A. (2018). Effects of Interictal Epileptiform Discharges on Cognition. Journal of Pediatric Epilepsy. https://doi.org/10.1055/s-0038-1676847
473. Meeusen, R., Cutsem, J. V., & Roelands, B. (2020). Endurance exercise‐induced and mental fatigue and the brain. Experimental Physiology. https://doi.org/10.1113/ep088186
474. Melykian, G., Ibrahim, F., Alarcón, G., Haddad, N., Hail, H. A., Deleu, D., Sheikh, L. E., Nofal, Y., & Mesraoua, B. (2024). New-Onset Refractory Status Epilepticus (NORSE). IntechOpen eBooks. https://doi.org/10.5772/intechopen.99004
475. Meléndez, R. I., & Kalivas, P. W. (2008). The Basic Science of Addiction. https://doi.org/10.1093/oso/9780195300550.003.0006
476. Merz, S. (1997). Treatment of Chronic Fatigue Syndrome. CRC Press eBooks. https://doi.org/10.1201/9781420001143-48
477. Mettu, S., Animireddy, D., Kanumuri, P. K., & Muppa, R. (2016). Symptomatic management of a child with cyclic vomiting syndrome. BMJ Case Reports. https://doi.org/10.1136/bcr-2016-216499
478. Metz-Lutz, D. M.-N., Martin, A. D. S., & Ponsot, G. (2003). Continuous spike-and-wave discharges during slow sleep.
479. Meyer, J. S., Obara, K., & Muramatsu, K. (1993). Diaschisis. Neurological Research. https://doi.org/10.1080/01616412.1993.11740164
480. Mignot, T., Maillard, L., Laprévote, V., Schwan, R., & Hingray, C. (2015). Crises psychogènes non épileptiques : une maladie émotionnelle ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2015.09.224
481. Miller, D. D. (2007). Sedation with Antipsychotics: Manage, Don't Accept Adverse 'Calming' Effect. Current psychiatry.
482. Miller, S. P., & Latal, B. (2009). Neurocognitive outcomes of term infants with perinatal asphyxia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511581281.050
483. Mir, J. A., Mushtaq, B., & Mushtaq, O. A. (2022). Clinical case report on bipolar affective disorder, mania. IP Journal of Paediatrics and Nursing Science. https://doi.org/10.18231/j.ijpns.2022.007
484. Mirawati, D. K. (2018). Managing antiepileptic drug, Starting, Changing and Stopping AED’s.
485. Miskoff, J. A., & Chaudhri, M. (2018). A Pediatric Case of Narcolepsy Presenting as Syncope. Cureus. https://doi.org/10.7759/cureus.3801
486. Mitrajit, S., RK, B., Malakar, J., & IK, S. (2020). Craniocerebral gunshot injury with no neurological deficit: the trending neurosurgical challenge. International Journal of Health Research and Medico Legal Practice. https://doi.org/10.31741/ijhrmlp.v6.i1.2020.16
487. Miyasato, K. (2013). [Psychiatric and psychological features of nicotine dependence].. PubMed.
488. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
489. Mocanu, C., Cernea, D., Enache, M., & Deca, A. G. (2009). [General anesthesia in ophthalmology].. PubMed.
490. Moch, S. (2011). Dysthymia: more than "minor".
491. Montag, D. (2021). Retrograde Amnesia – A Question of Disturbed Calcium Levels?. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2021.746198
492. Monti, M. M., Laureys, S., & Owen, A. M. (2010). The vegetative state. BMJ. https://doi.org/10.1136/bmj.c3765
493. Montreuil, M., & Derouesné, C. (1991). [Intellect and mood disorders in multiple sclerosis].. PubMed.
494. MOREIRA, C. D. F. A., Marinho, M., Lourenço, B., Fernandes, C. M., & Mota, T. (2015). Cognitive Impairment in Chronic Alcoholism. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30410-7
495. Moretti, R., Caruso, P., Ben, M. D., Gazzin, S., & Tiribelli, C. (2018). Thiamine and Alcohol for Brain Pathology: Super-imposing or Different Causative Factors for Brain Damage?. Current Drug Abuse Reviews. https://doi.org/10.2174/1874473711666180402142012
496. Morilak, D. A. (2007). Norepinephrine and stress. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544156.010
497. Morris, J. G., & McManus, D. Q. (1991). The neurology of aging: normal versus pathologic change.. PubMed.
498. Mortier, P., Vandenbulcke, M., & Gabriëls, L. (2014). [Confusional arousal: a rare cause of self-injurious behaviour].. PubMed.
499. Moshé, S. L., Tuchman, R. F., & Rapin, I. (2005). [Neurodevelopmental disorders and epilepsy].. PubMed.
500. Moukaddam, N., Cavazos, E., Nazario, M., Murtaza, S. T., & Shah, A. A. (2019). Depression and Its Impact on Adolescents. Psychiatric Annals. https://doi.org/10.3928/00485713-20190506-01
501. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
502. Mucci, A., Bucci, P., Giordano, G. M., Brando, F., & Galderisi, S. (2021). Apathy in schizophrenia: assessment in clinical settings and overlap with other dimensions of impairment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.159
503. Mukadam, N., Ritchie, K., & Sampson, E. L. (2007). Cholinesterase inhibitors for delirium: what is the evidence?. International Psychogeriatrics. https://doi.org/10.1017/s1041610207006205
504. Mukhopadhyay, S., & Banerjee, D. (2021). The complex conundrum of geriatric depression and dementias. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_21_21
505. Munro, C. A. (2018). The concept of mild cognitive impairment: a victim of its ubiquity. International Psychogeriatrics. https://doi.org/10.1017/s1041610218001850
506. Munster, B. C. V., Rooij, S. E. D., & Inouye, S. K. (2016). Delirium, drugs, toxins. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199655946.003.0022
507. Murawiec, S. (2010). [Some questions about the essence of delusions in the light of recent neurobiological findings].. Psychiatria Polska.
508. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
509. Mw, H., Eg, G., Hj, B., & Weel, C. V. (1997). [Chronic fatigue syndrome].. PubMed.
510. Mystakidou, K., Panagiotou, I., Parpa, E., & Tsilika, E. (2015). Sleep disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199656097.003.0086
511. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
512. Müller, C. P. (2013). Episodic Memories and Their Relevance for Psychoactive Drug Use and Addiction. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2013.00034
513. Naidech, A. M., & Maas, M. B. (2016). Critical Care Neurology Perspective on Delirium. Seminars in Neurology. https://doi.org/10.1055/s-0036-1592318
514. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
515. Nandi, P., & Lee, J. J. (2010). Improving the management of neuropathic pain.. PubMed.
516. Nantachai, G., Maes, M., Tran-Chi, V.-L., Hemrungrojn, S., & Tunvirachaisakul, C. (2024). Neurocognitive Features of Mild Cognitive Impairment and Distress Symptoms in Older Adults Without Major Depression.. PubMed. https://doi.org/10.2147/cia.s473730
517. Narayan, J. P., Verma, D., & Islam, R. (2022). Chronic Mania-A Case Report. International Journal of Psychiatric Nursing. https://doi.org/10.37506/ijpn.v9i1.18831
518. Nassisi, D., Korc, B., Hahn, S. A., Bruns, J., & Jagoda, A. (2006). The evaluation and management of the acutely agitated elderly patient.. PubMed.
519. Navarro, J. C., & Kofke, W. A. (2021). Perioperative Management of Acute Central Nervous System Injury. Perioperative Medicine. https://doi.org/10.1016/b978-0-323-56724-4.00024-1
520. Neary, D., & Snowden, J. S. (2002). Sorting out the Dementias. Practical Neurology. https://doi.org/10.1046/j.1474-7766.2002.00104.x
521. Nehring, S. M., Spurling, B. C., & Kumar, A. (2021). Transient Global Amnesia.
522. Nelson, M., Andel, R., Martínková, J., Čechová, K., Marková, H., & Hort, J. (2020). Moderating Effect of Cognitive Reserve on Brain Integrity and Cognitive Performance. Innovation in Aging. https://doi.org/10.1093/geroni/igaa057.912
523. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
524. Nickels, K. (2022). Childhood Neurologic Conditions: Epilepsy Management.. PubMed.
525. Nidode, P., Natarajan, C., Rajathi, G., Deepika, M. R., Shinkre, R., & Chouhan, D. S. (2024). Opioid dependency and intervention: A critical examination of the neurobiological foundations. Multidisciplinary Reviews. https://doi.org/10.31893/multirev.2023ss013
526. Nielson, K. A., Smith, J. C., Antuono, P., Lyons, J.-A., Hanson, R., Butts, A. M., Hantke, N., & Verber, M. (2013). Semantic Memory Functional MRI and Cognitive Function after Exercise Intervention in Mild Cognitive Impairment. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-130467
527. Nixon, S. J., & Phillips, J. (1999). Neurocognitive Deficits and Recovery in Chronic Alcohol Abuse. CNS Spectrums. https://doi.org/10.1017/s109285290001124x
528. Nofzinger, E. A., & Reynolds, C. F. (1997). 54 and Sleep Disorders.
529. North, C. S., & Yutzy, S. H. (2018). Delirium and Dementia (Neurocognitive Disorders). Oxford University Press eBooks. https://doi.org/10.1093/med/9780190215460.003.0013
530. Novikova, M. S. (2021). Treatment of non-demented vascular cognitive disorders. Meditsinskiy sovet = Medical Council. https://doi.org/10.21518/2079-701x-2021-19-57-65
531. Nunes, F. D. D., Freitas, P. H. B. D., Pinto, J. A. F., Souza, A. R. S., & Machado, R. M. (2016). Análise da prevalência de Síndrome Metabólica e fatores de risco associados em pacientes com Esquizofrenia Refratária. 12º Congresso Internacional da Rede Unida.
532. Nutt, D., & Nestor, L. J. (2018). Conclusion and overview. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0013
533. Näätänen, R., Kujala, T., & Light, G. A. (2019). Neurological disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198705079.003.0006
534. Ogawa, A. (2021). Long-Term Cognitive Function. CRC Press eBooks. https://doi.org/10.1201/9780429275524-96
535. Ogbonna, C. I., & Lembke, A. (2017). Tapering Patients Off of Benzodiazepines.. PubMed.
536. Ogino, Y., Bernaś, T., Greer, J. E., & Povlishock, J. T. (2021). Axonal injury following mild traumatic brain injury is exacerbated by repetitive insult and is linked to the delayed attenuation of NeuN expression without concomitant neuronal death in the mouse. Brain Pathology. https://doi.org/10.1111/bpa.13034
537. Ojeda, A. A. A., Li, B., & Patel, R. (2023). Substance-Induced Psychotic Disorder. Psychiatric Annals. https://doi.org/10.3928/00485713-20230314-01
538. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
539. Oreja‐Guevara, C., Blanco, T. A., Brieva, L., Pérez, M. Á. H., Meca‐Lallana, V., & Ramió‐Torrentà, L. (2019). Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.00581
540. Orhurhu, V., Roberts, J., Ly, N. K., & Cohen, S. P. (2019). Ketamine In Acute and Chronic Pain Management.
541. Oruch, R., Pryme, I. F., Engelsen, B. A., & Lund, A. (2017). Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s118438
542. Oscar‐Berman, M., & Mosher, S. M. (2010). Brain Injuries. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0143
543. Ospina, B., & Vélez, J. L. O. (2019). Espectro clínico y tratamiento del trastorno cognoscitivo y demencia asociada a la enfermedad de Parkinson. Acta neurológica colombiana. https://doi.org/10.22379/24224022248
544. Outhoff, K. (2016). Cognitive enhancement: a brief overview. South African Family Practice. https://doi.org/10.4102/safp.v58i1.4436
545. Outhoff, K. (2016). Insomnia disorder: when sleep plays coy, aloof and disdainful. South African Family Practice. https://doi.org/10.4102/safp.v58i3.4485
546. Ownby, R. L. (2006). Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults.. PubMed.
547. Oxman, T. E. (2015). Personality Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370054.ds18
548. OʼConnor, S., & Nussbaum, K. (1977). Impairment severity in seizure disorders: some suggestions for reliable assessment.. PubMed.
549. O’Donnell, B. F. (2007). Cognitive Impairment in Schizophrenia: A Life Span Perspective. American Journal of Alzheimer s Disease & Other Dementias®. https://doi.org/10.1177/1533317507304745
550. Palmer, B. W., McClure, F. S., & Jeste, D. V. (2001). Schizophrenia in Late Life: Findings Challenge Traditional Concepts. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220127883
551. Palmer, S. C., Zwieten, A. V., Saglimbene, V., Ruospo, M., & Strippoli, G. F. (2022). Neurocognitive Disorders. https://doi.org/10.1002/9781119105954.ch75
552. Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2018). Cognitive impairment in major depressive disorder. CNS Spectrums. https://doi.org/10.1017/s1092852918001207
553. Panebianco, M. (2024). Epilepsy and Neurocritical Care. https://doi.org/10.1007/978-981-99-8059-8_46
554. Panza, F., Capurso, C., D’Introno, A., Colacicco, A. M., Capurso, A., & Solfrizzi, V. (2006). PREVALENCE RATES OF MILD COGNITIVE IMPAIRMENT SUBTYPES AND PROGRESSION TO DEMENTIA. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2006.00874.x
555. Panza, F., Frisardi, V., Capurso, C., D’Introno, A., Colacicco, A. M., Seripa, D., Pilotto, A., Vendemiale, G., Capurso, A., & Solfrizzi, V. (2009). POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENT–NO DEMENTIA. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02236.x
556. Papacci, P., Serrao, F., Tesfagabir, M. G., Purcaro, V., Giannantonio, C., & Romagnoli, C. (2015). The management of pain: non-pharmacologic analgesia. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-41-s1-a27
557. Papmeyer, M., Sussmann, J. E., Hall, J., McKirdy, J., Peel, A. J., MacDonald, A. J., Lawrie, S. M., Whalley, H. C., & McIntosh, A. M. (2015). Neurocognition in individuals at high familial risk of mood disorders with or without subsequent onset of depression. Psychological Medicine. https://doi.org/10.1017/s0033291715001324
558. Paquin, V., Lebaron, N., Kraus, G., Yung, E., Iskric, A., Cervantes, P., Kolivakis, T., Saint-Laurent, M., Gobbi, G., Auger, N., & Low, N. (2022). Examining the association between duration of untreated illness and clinical outcomes in patients with major depressive and bipolar disorders. Journal of Affective Disorders Reports. https://doi.org/10.1016/j.jadr.2022.100324
559. Parker, R. S. (2012). Chronic Posttraumatic Stress. CRC Press eBooks. https://doi.org/10.1201/b10562-9
560. Parmet, S., Burke, A. E., & Glass, R. M. (2006). Insomnia. JAMA. https://doi.org/10.1001/jama.295.24.2952
561. Patchner, L. S., & DeWeaver, K. L. (2013). Disability: Neurocognitive Disabilities. Encyclopedia of Social Work. https://doi.org/10.1093/acrefore/9780199975839.013.542
562. Patel, D. R., & Merrick, J. (2020). Neurodevelopmental and neurobehavioral disorders. Translational Pediatrics. https://doi.org/10.21037/tp.2020.02.03
563. Patki, J., & Ravinutala, S. (2016). Post-operative cognitive dysfunction – A brief review. Journal of Medical and Scientific Research. https://doi.org/10.17727/jmsr.2016/4-010
564. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
565. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
566. Paulson, G. W. (1981). Transient global amnesia. Postgraduate Medicine. https://doi.org/10.1080/00325481.1981.11715684
567. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
568. Peacock, J., & Benca, R. M. (2010). Narcolepsy: clinical features, co-morbidities & treatment.. PubMed.
569. Pejović-Nikolić, S. (2011). [Neurobiological disturbances in insomnia: clinical utility of objective sleep measures].. PubMed.
570. Penubarthi, S., Miryala, R., Vatte, V. R., & Kandrakonda, S. (2022). Neuropsychological impairments in a young-onset Marchiafava–Bignami disease with alcohol-dependence syndrome. Telangana Journal of Psychiatry. https://doi.org/10.4103/tjp.tjp_31_22
571. Perez‐Polo, R. (1991). Nerve Growth Factor and Aging: A Hypothesis. Birkhäuser Boston eBooks. https://doi.org/10.1007/978-1-4899-6738-1_50
572. Petersen, R. C. (2004). Mild cognitive impairment (MCI), amnestic type. https://doi.org/10.1093/oso/9780195177442.003.0050
573. Picard, L. S., Lindsay, S., Strawn, J. R., Kaneria, R. M., Patel, N. C., & Keck, P. E. (2008). Atypical Neuroleptic Malignant Syndrome: Diagnostic Controversies and Considerations. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.28.4.530
574. Piccirilli, M., D’Alessandro, P., Finali, G., & Piccinin, G. L. (1994). Neuropsychological Follow-Up of Parkinsonian Patients with and without Cognitive Impairment. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000106689
575. Piccolo, A. C., Campos, L. M. G., & Audi, M. (2025). RELAÇÃO ENTRE A QUALIDADE DO SONO, PERCEPÇÃO CORPORAL E OS SINTOMAS MOTORES E SENSITIVOS EM PESSOAS COM ESCLEROSE MÚLTIPLA REMITENTE-RECORRENTE. Aracê.. https://doi.org/10.56238/arev7n8-002
576. Pieracci, G., Satriano, F., D'agostino, A., Rodini, M., Caltagirone, C., Formisano, R., Vinicola, V., & Carlesimo, G. A. (2025). Accelerated long-term forgetting: Design and validation of a neuropsychological tool in healthy subjects and diagnostic accuracy in a group of subjects with severe acquired brain injury. Applied Neuropsychology Adult. https://doi.org/10.1080/23279095.2024.2449564
577. Pikirenia, U., Fedotov, I., Tuchina, O., & Kapytau, A. U. (2017). Cognitive impairment due to alcohol abuse: current status of research. Vestnik of Saint Petersburg University Medicine. https://doi.org/10.21638/11701/spbu11.2017.306
578. Pinelli, P. (2008). Neural sequences: deductive principles and rules.. Functional Neurology.
579. Pitel, A., Lannuzel, C., Viader, F., Vabret, F., Eustache, F., & Beaunieux, H. (2013). Alcoolo-dépendance et syndrome de Korsakoff : un continuum ?. Revue de neuropsychologie. https://doi.org/10.3917/rne.053.0179
580. Pitel, A.-L. (2007). Les troubles cognitifs dans l'alcoolisme chronique avec et sans syndrome de Korsakoff : analyse neuropsychologique et remédiation cognitive.
581. Pizov, A. V. (2022). Peculiarities of insomnia in men and women at different age periods. Meditsinskiy sovet = Medical Council. https://doi.org/10.21518/2079-701x-2022-16-21-112-118
582. Playfor, S. (2002). Neuromuscular Blocking Agents in Critically Ill Children. Paediatric and Perinatal Drug Therapy. https://doi.org/10.1185/146300902322125145
583. Poljak, T. H. (2018). "Alzheimer’s dementia ". Hospice and Palliative Medicine International Journal. https://doi.org/10.15406/hpmij.2018.02.00084
584. Pomerleau, C. S. (1997). Co‐factors for smoking and evolutionary psychobiology. Addiction. https://doi.org/10.1111/j.1360-0443.1997.tb03371.x
585. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
586. Powlishta, K. K., Storandt, M., Mandernach, T., Hogan, E., Grant, E., & Morris, J. C. (2004). Absence of Effect of Depression on Cognitive Performance in Early-Stage Alzheimer Disease. Archives of Neurology. https://doi.org/10.1001/archneur.61.8.1265
587. Pramesti, F. A., Husna, M., Kurniawan, S. N., & Rahayu, M. (2017). DIAGNOSIS AND MANAGEMENT OF NONCONVULSIVE STATUS EPILEPTICUS (NCSE). MNJ (Malang Neurology Journal). https://doi.org/10.21776/ub.mnj.2017.003.01.6
588. Prasad, D., & Manjula, S. (2011). A state of reversed hypoxic encephalopathy following attempted suicidal hanging: a boon. Medicine Science and the Law. https://doi.org/10.1258/msl.2011.010159
589. Pratibha, S. (2010). Etiology of Late Onset Seizures.
590. Pratt, R. W., & Weimer, L. H. (2005). Medication and Toxin-Induced Peripheral Neuropathy. Seminars in Neurology. https://doi.org/10.1055/s-2005-871329
591. Praško, J., Herman, E., Raszka, M., Hovorka, J., & Doubek, P. (2007). Disociativní poruchy a jejich léčba. Medicína pro praxi.
592. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
593. Previgliano, I., Andres, B., & Ciesielczyk, P. J. (2015). Long-term Cognitive Impairment after Critical Illness – Definition, Incidence, Pathophysiology and Hypothesis of Neurotrophic Treatment. European Neurological Review. https://doi.org/10.17925/enr.2015.10.02.195
594. Prichep, L., John, E. R., Fridman, J., & Easton, P. A. (1988). Neurometrics: Computer-Assisted Differential Diagnosis of Brain Dysfunctions. Science. https://doi.org/10.1126/science.3336779
595. Prunnlechner, R. (2012). [Forensic aspects of schizophrenia].. PubMed.
596. Pujar, S., & Scott, R. C. (2019). Long-term outcomes after childhood convulsive status epilepticus. Current Opinion in Pediatrics. https://doi.org/10.1097/mop.0000000000000825
597. Pusparani, A. (2021). A Review on Insomnia: The Sleep Disorder. Scientia Psychiatrica. https://doi.org/10.37275/scipsy.v3i2.53
598. Pyszora, N., Fahy, T., & Kopelman, M. D. (2014). Amnesia for violent offenses: factors underlying memory loss and recovery.. PubMed.
599. Rabins, P. V. (1991). Psychosocial and Management Aspects of Delirium. International Psychogeriatrics. https://doi.org/10.1017/s1041610291000765
600. Radmanović, M. B., & Burgić, S.-S. (2020). Comorbidity in Children and Adolescents with ADHD. IntechOpen eBooks. https://doi.org/10.5772/intechopen.94527
601. Rady, M. Y., & Verheijde, J. L. (2009). Continuous Deep Sedation Until Death: Palliation or Physician-Assisted Death?. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909109348868
602. Raga, S., Specchio, N., Rheims, S., & Wilmshurst, J. M. (2021). Developmental and epileptic encephalopathies: recognition and approaches to care. Epileptic Disorders. https://doi.org/10.1684/epd.2021.1244
603. Rahma, F. (2021). Depression and Conversion to Dementia in Mild Cognitive Impairment. Scientia Psychiatrica. https://doi.org/10.37275/scipsy.v3i1.48
604. Raičević, B., Janković, S. V., Gojak, R., Dabanović, V., & Јаnkovic, S. (2023). Long-term outcomes in refractory status epilepticus. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2023.2292143
605. Rajput, A., Uitti, R. J., Sudhakar, S., & Rozdilsky, B. (1989). Parkinsonism and neurofibrillary tangle pathology in pigmented nuclei. Annals of Neurology. https://doi.org/10.1002/ana.410250612
606. Rakofsky, J. J. (2016). RELAPSE: Answers to Why a Patient Is Having a New Mood Episode. Current psychiatry.
607. Ramakrishnan, K., & Scheid, D. C. (2012). Treatment options for Insomnia. The Nurse Practitioner. https://doi.org/10.1097/01.npr.0000410656.55255.1c
608. Ramdhani, R., & Frucht, S. J. (2014). Movement disorders emergencies. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175845.028
609. Rao, S. M., & Doraiswamy, P. M. (2004). Treating cognitive deficits in multiple sclerosis. Neurology. https://doi.org/10.1212/01.wnl.0000146628.30692.15
610. Rayi, A., & Mandalaneni, K. (2021). Encephalopathic EEG Patterns. StatPearls.
611. Rees, S., Harding, R., & Walker, D. W. (2011). The biological basis of injury and neuroprotection in the fetal and neonatal brain. International Journal of Developmental Neuroscience. https://doi.org/10.1016/j.ijdevneu.2011.04.004
612. Remschmidt, H., & Theisen, F. (2012). Early-Onset Schizophrenia1. Neuropsychobiology. https://doi.org/10.1159/000338548
613. Rengel, K. F., Hayhurst, C. J., Pandharipande, P. P., & Hughes, C. G. (2019). Long-term Cognitive and Functional Impairments After Critical Illness. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004066
614. Renzullo, A. M., Benvenuto, S., Nait, G., & Pennesi, M. (2024). L'enuresi notturna: in quadramento e gestione. Medico e Bambino. https://doi.org/10.53126/meb43499
615. Retnaswami, C., Annapoorni, C. V., Mailankody, P., Katragadda, P., Pillai, S., Rangarajan, A., Padmanabha, H., & Pendharkar, H. (2020). Tumors Masquerading as Neurological Diseases: A Caution for Clinicians in Planning Diagnosis and Treatment. Neurology India. https://doi.org/10.4103/0028-3886.280647
616. Reuter, M. (2009). Melodiewahrnehmung ohne äußeren Reiz. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628605
617. Reznik, M., & Claassen, J. (2018). Seizures and Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199375349.003.0008
618. Riaz, A., Shahid, Q., Yousaf, H. M., Gul, U., Shah, S. S., Hidayat, A., Hamid, T., Rahman, A. U., Usman, M., Khan, M. K., Muhtiar, R., & Khalid, B. (2024). Mirtazapine in Primary Insomnia: Case report and Literature review. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2024.23.1.2213
619. Riaz, Y., & Sergi, C. (2021). Feeding Disability In Children.
620. Ribeiro, J., Pestana‐Santos, A., & Madeira, N. (2017). Défices Cognitivos na Perturbação Depressiva Major. https://doi.org/10.25752/psi.12761
621. Richardson, L., & Adams, S. (2018). Cognitive Deficits in Patients With Depression. The Journal for Nurse Practitioners. https://doi.org/10.1016/j.nurpra.2018.03.006
622. Rickels, K. (1986). The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1986.tb08990.x
623. Ridder, D. D. (2007). Brain and Nerve Stimulation for Mood Enhancement. Philosophica. https://doi.org/10.21825/philosophica.82182
624. Ridley, N., & Draper, B. (2014). Alcohol-related dementia and brain damage: a focus on epidemiology. https://doi.org/10.4324/9781315742922-8
625. Riemann, D., Zerssen, D. V., Berger, M., Dose, M., Doerr, P., Krieg, C. J., Bossert, S., Pirke, K. M., Dolhofer, R., & Müller, O. A. (1986). The nature of neuroendocrine abnormalities in depression: a controversial issue in contemporary psychiatry.. PubMed.
626. Rigaud, J., Lheureux, P., & Sauder, P. (2006). Prise en charge symptomatique : neurologique, respiratoire, hémodynamique et hépatique des intoxications graves par médicaments et substances illicites. Réanimation. https://doi.org/10.1016/j.reaurg.2006.08.002
627. Rigolet, M., Aouizerate, J., Couette, M., Ragunathan-Thangarajah, N., Aoun-Sebaïti, M., Gherardi, R. K., Cadusseau, J., & Authier, F. (2014). Clinical Features in Patients with Long-Lasting Macrophagic Myofasciitis. Frontiers in Neurology. https://doi.org/10.3389/fneur.2014.00230
628. Ritzmann, C., Silva, L. H. A. D., & Kupfer, R. (2015). Impact of assessment and treatment of neuropathic pain in patients with chronic diabetic neuropathy assisted in a diabetes reference service. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/1758-5996-7-s1-a34
629. Roberts, A. J., & Koob, G. F. (1997). The neurobiology of addiction: an overview.. PubMed.
630. Robinson, P. (2014). Severe and enduring eating disorders: recognition and management. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.113.011841
631. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
632. Rodríguez, A. V. A. (2021). Síndrome dis-ejecutivo: perfil neuropsicológico e intervención neuropsicológica..
633. Rodríguez, F. D., Sánchez, M. L., & Coveñas, R. (2023). Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108656
634. Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1991). Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults.. Journal of Abnormal Psychology. https://doi.org/10.1037/0021-843x.100.2.214
635. Romesser, C. (2017). Delirium. CRC Press eBooks. https://doi.org/10.1201/9781315373904-8
636. Ronchetto, M., & Ronchetto, F. (2022). The intricate connection between depression and dementia as a major challenge for clinicians. Journal of Gerontology and Geriatrics. https://doi.org/10.36150/2499-6564-n518
637. Rose, M. E., & Grant, J. E. (2010). Alcohol-Induced Blackout. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0b013e3181e1299d
638. Ross, A. (2017). Medico-legal aspects of peripheral nerve injury. Bone and Joint 360. https://doi.org/10.1302/2048-0105.65.360554
639. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
640. Rothenberger, A., & Hüther, G. (1997). [The role of psychosocial stress in childhood for structural and functional brain development:neurobiological basis of developmental psychopathology].. PubMed.
641. Rowe, J. B. (2010). Conversion disorder: understanding the pathogenic links between emotion and motor systems in the brain. Brain. https://doi.org/10.1093/brain/awq096
642. Rowe, J. B., & Murley, A. G. (2023). Reserve, Resilience and Resistance to Neurodegeneration. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.080
643. Rubiales, Á. S., Duarte, F. B., & Valle, M. L. D. (2015). [Do we need a more precise definition of what sedation is?].. PubMed.
644. Rubin, M. N., & Rabinstein, A. A. (2017). Electrolyte Disturbances. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199937837.003.0183
645. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
646. Rue, A. L., & Jarvik, L. F. (1987). Cognitive Function and Prediction of Dementia in Old Age. The International Journal of Aging and Human Development. https://doi.org/10.2190/dv3r-pbjq-e0ft-7w2b
647. Ruiz-Tagle, C., Costa, B. G., Ortega, A., Bello-Lepe, S., González-Hidalgo, C., Rohde, G., Iturrieta, I., Osorio, M., & Cáseres, A. (2021). Efecto de una intervención no farmacológica multidimensional en un grupo de personas con deterioro cognitivo leve. Revista médica de Chile. https://doi.org/10.4067/s0034-98872021001101569
648. Ruoff, C., & Rye, D. B. (2016). The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2016.1208643
649. Rupani, K., & Adarkar, S. (2022). Optimizing Patient Care in Sleep Disorders. Routledge eBooks. https://doi.org/10.4324/9780429030260-28
650. Ryall, R. W. (1989). Affective and manic depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511526923.013
651. Ryu, H. U., Kim, H. J., Shin, B., & Kang, H. G. (2024). Clinical approaches for poststroke seizure: a review. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1337960
652. Río, M. S. D., Diaz, J. A., Martínez, Y., & Monterrey, P. O. C. (2017). Síndrome de deficiencia del transportador de glucosa tipo 1. Reporte de un caso de rehabilitación. Revista Cubana de Medicina Física y Rehabilitación.
653. Rönnbäck, L., Persson, M., & Olsson, T. (2007). »Trött i hjärnan« osynligt handikapp som kan ge stora problem. Läkartidningen/Läkartidningen.
654. Sa, C., Em, S., Mv, G., Kr, A., Pirogov, Y. A., & Ne, C. (2012). [Neuroprotection in epilepsy].. PubMed.
655. Saberi, B. (2020). Cognitive Deficits in Cocaine Users. Open Access Journal of Addiction and Psychology. https://doi.org/10.33552/oajap.2020.03.000560
656. Sadek, J., Pergam, S. A., Harrington, J., Echevarria, L., Davis, L. E., Goade, D., Harnar, J., Nofchissey, R. A., Sewell, C. M., Ettestad, P., & Haaland, K. Y. (2009). Persistent neuropsychological impairment associated with West Nile virus infection. Journal of Clinical and Experimental Neuropsychology. https://doi.org/10.1080/13803390902881918
657. Sadowski, M. (2010). Toward improving the diagnosis of Alzheimer's Disease.
658. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
659. Sakalauskaitë-Juodeikienë, E., & Masaitienė, R. (2018). Naujas nemigos apibrėžimas, etiopatogenezė, diagnostikos ir gydymo algoritmas. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.20
660. Saksono, A. B. (2021). Postoperative Cognitive Dysfunction. Open Access Indonesian Journal of Medical Reviews. https://doi.org/10.37275/oaijmr.v1i3.38
661. Saksono, A. B. (2021). Postoperative Cognitive Dysfunction. Open Access Indonesian Journal of Medical Reviews. https://doi.org/10.37275/oaijmr.v1i3.557
662. Sander, R. (2015). Biomarkers to track progress of genetic frontotemporal dementia. Nursing Older People. https://doi.org/10.7748/nop.27.6.15.s19
663. Sandi, C. (2013). Stress and cognition. Wiley Interdisciplinary Reviews Cognitive Science. https://doi.org/10.1002/wcs.1222
664. Santana, C. L., & Saúco, M. Á. (2006). Levodopa y alteraciones cognitivas en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.4302.2005571
665. Sathitruangsak, C., & Dechaphunkul, A. (2014). Neurological Complications of Chemotherapy and Radiotherapy in Cancer Patients. DOAJ (DOAJ: Directory of Open Access Journals).
666. Saunders, E. F., McInnis, M. G., & Greden, J. F. (2007). Evidence for the need of long-term treatment of major depression. Primary psychiatry.
667. Scaravilli, F. (1998). Neuropathology of Epilepsy. WORLD SCIENTIFIC eBooks. https://doi.org/10.1142/3505
668. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
669. Schildkrout, B. (2014). Dementia. https://doi.org/10.1002/9781394260447.ch12
670. Schildkrout, B. (2014). Disease #40: Narcolepsy. https://doi.org/10.1002/9781394260447.ch68
671. Schildkrout, B. (2014). Disease #43: Nocturnal Eating: Night‐Eating Syndrome (NES). https://doi.org/10.1002/9781394260447.ch71
672. Schildkrout, B. (2014). Disease #65: Transient Global Amnesia. https://doi.org/10.1002/9781394260447.ch93
673. Schjøtt, J., & Raknes, G. (2010). Håndtering av seponeringsreaksjoner. Tidsskrift for Den norske legeforening. https://doi.org/10.4045/tidsskr.09.1088
674. Schmidt, M. H., Dekkers, M., Baillieul, S., Jendoubi, J., Wulf, M.-A., Wenz, E., Fregolente, L., Vorster, A., Gnarra, O., & Bassetti, C. L. (2021). Measuring Sleep, Wakefulness, and Circadian Functions in Neurologic Disorders. Sleep Medicine Clinics. https://doi.org/10.1016/j.jsmc.2021.08.005
675. Schmidtke, K., Metternich, B., & Hull, M. (2007). Therapy of non-organic memory disorder. Aktuelle Neurologie. https://doi.org/10.1055/s-2007-987738
676. Schneider, L. S., & Abou‐Saleh, U. B. M. T. (2002). Neurochemistry. https://doi.org/10.1002/0470846410.ch72
677. Schredl, M., Schramm, F., Valli, K., Mueller, E. M., & Sandman, N. (2020). Nightmare Distress Questionnaire: associated factors. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.8824
678. Schwerthöffer, D., Fatke, B., & Förstl, H. (2020). Dilemmasituation: Nächtlicher Unruhezustand beim älteren Patienten.
679. Schülke, R., Liepach, K., Brömstrup, A., Folsche, T., Deest, M., Bleich, S., Neyazi, A., Frieling, H., & Maier, H. B. (2022). Neurological soft signs are increased in major depressive disorder irrespective of antidepressant treatment. Pharmacopsychiatry. https://doi.org/10.1055/s-0042-1757665
680. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
681. Seltzer, B. (2007). Cognitive Complaints: Their Role in Detecting MCI and Dementia.
682. Senzaki, A. (2018). Physical Activity/Exercise Therapy for Neuropsychological Dysfunction after Brain Injuries. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.55.198
683. Sesar, Á., Arbelo, J. M., & Val, J. L. D. (2011). Treatment of Parkinson Disease, Time and Dosage. The Neurologist. https://doi.org/10.1097/nrl.0b013e31823968d3
684. Sewell, R. D. E. (2018). Neuropathic pain models and outcome measures: a dual translational challenge. Annals of Translational Medicine. https://doi.org/10.21037/atm.2018.09.58
685. Shaikh, S., & Lakshmi, R. (2014). Delayed awakening after anaesthesia- A challenge for an anaesthesiologist. International Journal of Biomedical and Advance Research. https://doi.org/10.7439/ijbar.v5i8.829
686. Shalamberidze, D., Awad, Y. A., Höpfner, J., Kluge, G., & Benes, L. (2021). Suggestion For a New Classification of Postoperative Neurological Complications (CPNC) in Neurosurgery. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-353350/v1
687. Sharp, S. I., Francis, P. T., & Ballard, C. (2005). Neurochemistry of severe dementia. Reviews in Clinical Gerontology. https://doi.org/10.1017/s0959259805001681
688. Sheehan, B. (2020). Delirium. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0627
689. Sheehan, B. (2020). Dementia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0628
690. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
691. Sherchan, S., & Joshi, D. (2015). The Man Behind the Royal Massacre. Journal of Nepal Medical Association. https://doi.org/10.31729/jnma.2749
692. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
693. Shprecher, D., & Mehta, L. (2010). The syndrome of delayed post-hypoxic  leukoencephalopathy.. PubMed.
694. Shuxratovich, S. S., Musurmonovich, A. S., & Shodiyorovich, N. L. (2020). Neuroses And The Factors Which Contribute To It. The American Journal of Medical Sciences and Pharmaceutical Research. https://doi.org/10.37547/tajmspr/volume02issue11-24
695. Silva, T. D. O., Leite, J. R., Bezerra, W. D. S. P., Lima, M. B. L. D., & Fiorin, P. M. (2017). A DEPRESSÃO NA TERCEIRA IDADE:RELATO DE EXPERIÊNCIA DE UMA ATIVIDADE EDUCATIVA.
696. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
697. Silverstein, E., Basiru, T., Aulakh, M., Verzura, M. L., & Suarez, R. (2025). Management of Acute Onset Catatonia Postpartum in a Patient With a History of Major Depressive Disorder With Psychotic Features: A Case Report. Cureus. https://doi.org/10.7759/cureus.84392
698. Simms, S., Kuh, E., & D’Angio, G. J. (2005). Psychosocial aspects of the histiocytic disorders: staying on course under challenging clinical circumstances. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545252.022
699. Singh, S. (2015). Mental health in infancy. International Journal of Clinical & Medical Imaging. https://doi.org/10.4172/2376-0249.1000393
700. Sinha, S., Moss, A. J., & Calkins, H. (2007). The etiology of sudden death. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544828.014
701. Skike, C. E. V., Goodlett, C. R., & Matthews, D. B. (2019). Acute Alcohol and Cognition: Remembering What It Causes Us to Forget. Author eBooks.
702. Skoog, I. (2011). Psychiatric Disorders in the Elderly. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371105600702
703. Slavin, K. V., Isagulyan, E. D., Mikhailova, V. A., & Aslakhanova, K. S. (2021). Prospects of neuromodulation for chronic pain. Brain Disorders. https://doi.org/10.1016/j.dscb.2021.100027
704. Smego, R. A. (1982). The Neuroleptic Malignant Syndrome. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1982.00340190139021
705. Smith, J., & Seirafi, J. (2013). Delirium and Dementia.
706. Smith, P. J., & Blumenthal, J. A. (2015). Exercise and Physical Activity in the Prevention and Treatment of Depression. Routledge eBooks. https://doi.org/10.4324/9780203132678.ch8
707. Smith, W. (2013). Adverse drug reactions - allergy? side-effect? intolerance?. PubMed.
708. Sobrido, M., Dias-Silva, J. J., & Quintáns, B. (2009). [Behavioral disorders in Parkinson's disease. Genetic, pharmacological and medico-legal aspects]..
709. Solmi, M., Bortolato, B., Veronese, N., Stubbs, B., Herrmann, N., & Carvalho, A. F. (2019). Pharmacological Interventions for Cognitive Dysfunction in Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198810940.003.0018
710. Song, T. (2018). The relationship between general anesthesia and postoperative behavioral and cognitive change. Chin J Postgrad Med. https://doi.org/10.3760/cma.j.issn.1673-4904.2018.10.021
711. Song, Y., Jung, L., & Richards, K. C. (2012). Dementia and sleep disturbances. Aging Health. https://doi.org/10.2217/ahe.11.93
712. Sordi, A. O., Schuch-Goi, S. B., & Diemen, L. V. (2019). Substance abuse and neuroprogression. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198787143.003.0012
713. Southwick, S. M., Bremner, J. D., & Charney, D. S. (1997). Neuroanatomical Correlates Of The Effects Of Stress On Memory: Relevance To The Validity Of Memories Of Childhood Abuse. Trauma and Memory. https://doi.org/10.1093/oso/9780195100655.003.0008
714. Spence, S. A. (2006). All in the mind? The neural correlates of unexplained physical symptoms. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.12.5.349
715. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
716. Spira, A. P., Chen-Edinboro, L. P., Wu, M. N., & Yaffe, K. (2014). Impact of sleep on the risk of cognitive decline and dementia. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000106
717. Squire, L. R. (1989). Amnesia. Birkhäuser Boston eBooks. https://doi.org/10.1007/978-1-4899-6768-8_5
718. Srivastav, M. (2014). Causes of Hypersomnia – Narcolepsy. DOAJ (DOAJ: Directory of Open Access Journals).
719. Stahl, S. M., & Morrissette, D. A. (2018). Treatment of Secondary Behavioral Symptoms of Dementia. https://doi.org/10.1017/9781107706842.008
720. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
721. Steinhausen, H., & Gillberg, C. (2006). Brain disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543807.002
722. Steinmetz, J., & Rasmussen, L. S. (2015). Peri‐operative cognitive dysfunction and protection. Anaesthesia. https://doi.org/10.1111/anae.13308
723. Stevens, R. D., & Kornbluth, J. (2016). Causes and diagnosis of unconsciousness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199600830.003.0228
724. Stoffels, J. M. J., Munster, B. C. V., & Muller, M. (2020). [Delirium in the elderly; article for education and training purposes]..
725. Stoffels, J. M. J., Munster, B. C. V., & Muller, M. (2020). Delier bij ouderen.
726. Stolpmann, G., Fromberger, P., Jordan, K., Schwerdtner, J., & Müller, J. (2010). Patienten mit einer wahnhaften Depression in der Maßregel nach § 63 StGB. Forensische Psychiatrie Psychologie Kriminologie. https://doi.org/10.1007/s11757-010-0059-2
727. Stone, J., & Sharpe, M. (2020). Functional neurological symptom disorder (conversion disorder). Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0133
728. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
729. Stoner, C. R., Knapp, M., Luyten, J., Kung, C. S. J., Richards, M., Long, R., & Rossor, M. N. (2020). The cognitive footprint of medication: A review of cognitive assessments in clinical trials. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.13151
730. Suchyta, M. R., & Hopkins, R. O. (2007). Neurologic Sequelae in Critical Illness: Evaluation and Outcomes. Current Respiratory Medicine Reviews. https://doi.org/10.2174/157339807782359904
731. Sugimoto, A., Futamura, A., & Kawamura, M. (2013). [Epilepsy and cognitive dysfunction].. PubMed.
732. Sun, M. (2018). Executive functioning: perspectives on neurotrophic activity and pharmacology. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000427
733. Sunderland, T., Molchan, S., Little, J. T., Bahro, M., Putnam, K., & Weingartner, H. (1997). Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans.. PubMed.
734. Suárez-Escudero, J. C. (2014). Discapacidad y neurociencias: la magnitud del déficit neurológico y neuro psiquiátrico. Acta neurológica colombiana.
735. Sánchez, J. M. (2014). Responsabilidad penal del drogodependiente. Revista electrónica de ciencia penal y criminología.
736. Tackenberg, B., Ziemssen, T., Berthele, A., Kieseier, B. C., Rauer, S., Baum, K., Hellwig, K., Limmroth, V., Schippling, S., Heesen, C., Arbizu, T., Martínez‐Yélamos, S., Montalbán, X., Fernández-Fernández, Ó., Casanova, B., Ferrer, F. C., Meca, J., Hughes, B., Weinstock‐Guttman, B., ... Tornatore, C. (2015). MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology. https://doi.org/10.1212/wnl.0000000000001255
737. Takada, S. (2020). Prevention and diagnosis of neuropathy during dental treatment. Japanese Journal of Oral & Maxillofacial Surgery. https://doi.org/10.5794/jjoms.66.530
738. Takeshita, J., Thompson, D., & Nicolson, S. E. (2007). Medication-Induced Psychosis. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543784.023
739. Taliyan, R., Singh, G., & Sharma, P. (2012). None. International Journal of Pharmaceutical Sciences and Research. https://doi.org/10.13040/ijpsr.0975-8232.3(10).3530-42
740. Tamam, L., & Zengin, M. (2011). Aralikli Patlayici Bozukluk Intermittent Explosive Disorder.
741. Tandon, R., Dutchak, D., & Greden, J. F. (1989). Cholinergic Syndrome following Anticholinergic Withdrawal in a Schizophrenic Patient Abusing Marijuana. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.154.5.712
742. Tarabeih, M. (2018). Mental Disorders, Addictions Related To Long Hospitalization Days That Require Double Diagnosis in Moldova. Biomedical Journal of Scientific & Technical Research. https://doi.org/10.26717/bjstr.2018.05.0001140
743. Tasbihgou, S. R., & Absalom, A. (2020). Postoperative neurocognitive disorders. Korean journal of anesthesiology. https://doi.org/10.4097/kja.20294
744. Taxirovna, D. S., Otabekovich, S. A., & Taxirovna, D. A. (2021). Prevention and Treatment of Cognitive Dysfunctions in Patients with Discirculatory Enfephalopathy. Annals of the Romanian Society for Cell Biology.
745. Tedeschi, G., Russo, A., & Tessitore, A. (2015). Functional neuroimaging: the adaptive mechanisms in migraine. The Journal of Headache and Pain. https://doi.org/10.1186/1129-2377-16-s1-a6
746. Terrés-Jiménez, B., Domínguez-Cabañero, E. M., González-Vivas, C., García-Parreño, B., Diego-Castaño, S., Gesler, M. A., Entrambasaguas, M. D., & Lorente-Rovira, E. (2022). Variables associated with the success of group cognitive behavioral therapy for insomnia: preliminary results.. PubMed.
747. Terçariolli, B. I., Rosa, J. M., Vieira, G. P., Cardoso, R., & Lage, P. S. (2024). RESUMO Introdução: Os transtornos mentais são definidos como sendo síndromes caracterizadas por uma perturbação clinicamente expressiva na cognição, na regulação emocional ou no comportamento de um indivíduo, que refletem uma disfunção nos processos psicológicos, biológicos ou de desenvolvimento subjacentes ao funcionamento mental. Estes estão frequentemente associados ao sofrimento ou às incapacidades. Sabe-se que uma das características marcantes de determinados transtornos está relacionada à…. Revista fisio&terapia.. https://doi.org/10.69849/revistaft/fa1020240911111905
748. Thakur, N., Black, M., Russo, S. N., & Koenig, M. K. (2022). Neurometabolic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197574317.003.0020
749. Thibaut, F. (2018). Psychiatric disorders: neurodevelopmental disorders, neurodegenerative disorders, or both?. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2018.20.4/fthibaut
750. Thio, L. L., & Wainwright, M. S. (2015). Status epilepticus. Neurology. https://doi.org/10.1212/wnl.0000000000001670
751. Thirumalaikolundusubramanian, P., & Ramadevi, K. (2016). DEVELOPMENTAL DELAY AND MENTAL RETARDATION IN PATIENTS WITH INHERITED METABOLIC DISORDERS. International Journal of Pharma and Bio Sciences.
752. Thivaharana, Y., Deepthi, I., Kitulwatteb, G., & Thivaharan, Y. (2022). None. International Archives of Internal Medicine. https://doi.org/10.23937/2643-4466/6/1
753. Tholen, A. J., Hoek, H. W., & Giel, R. (1987). The Classification and Assessment of Intellectual and Other Psychological Impairments in the Mentally Disabled. International Journal of Mental Health. https://doi.org/10.1080/00207411.1987.11449076
754. Thomas, N., & Pantelis, C. (2015). Psychotic Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp535
755. Thomas, P., & Gélisse, P. (2008). Champ 9 – états de mal épileptiques non convulsifs☆. Réanimation. https://doi.org/10.1016/j.reaurg.2008.09.027
756. Thomas, P., & Hazif‐Thomas, C. (2008). NEWLY UNDERSTANDING DEPRESSION IN ELDERLY. Gerontologie et societe.
757. Thorburn, D. R., Rahman, J., & Rahman, S. (2014). Mitochondrial DNA-Associated Leigh Syndrome and NARP. University of Washington, Seattle eBooks.
758. Tiberio, P. J., Prendergast, N., & Girard, T. D. (2021). Treatment of Delirium During Critical Illness. Annual Review of Medicine. https://doi.org/10.1146/annurev-med-042220-013015
759. Tjia, J., Briesacher, B. A., Peterson, D. J., Liu, Q., Andrade, S. E., & Mitchell, S. L. (2014). Use of Medications of Questionable Benefit in Advanced Dementia. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2014.4103
760. Toda, K. (2018). The Medication Guidelines for Neuropathic Pain Including Fibromyalgia is justified from a Scientific Viewpoint, However, it does Not Necessarily Agree with Clinical Priority.
761. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
762. Tonković, D., Adam, V. N., Kovačević, M., Bogović, T. Z., Drvar, Z., & Baronica, R. (2012). [Perioperative disorders of mental functions].. PubMed.
763. Tony, B. (2016). Sports-Related Traumatic Brain Injuries: Mini Review. Journal of Neurology & Stroke. https://doi.org/10.15406/jnsk.2016.04.00129
764. Topp, L. (2011). Suicide in Australia: Where Do Alcohol and Other Drugs Fit In?. Of Substance: The National Magazine on Alcohol, Tobacco and Other Drugs.
765. Torpy, J. M. (2009). Mild Cognitive Impairment. JAMA. https://doi.org/10.1001/jama.302.4.452
766. Torpy, J. M. (2010). Delirium. JAMA. https://doi.org/10.1001/jama.304.7.814
767. Torre, J. L. F., Pérez, R. G., & Zarzosa, M. V. (2003). Estado epiléptico no convulsivo. Revista de Neurología. https://doi.org/10.33588/rn.3708.2003146
768. Touze, M.-D., Potel, G., & Baron, D. (1993). [Acute ethyl alcohol intoxication].. PubMed.
769. Treede, R. (2012). Peripheral and Central Mechanisms of Neuropathic Pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195394702.003.0002
770. Treiman, D. M. (1993). Generalized Convulsive Status Epilepticus in the Adult. Epilepsia. https://doi.org/10.1111/j.1528-1157.1993.tb05902.x
771. Tripathi, M., & Rai, N. (2014). Sleep and cognition. Indian Journal of Sleep Medicine. https://doi.org/10.5958/0974-0155.2015.00003.0
772. Tripathi, M., & Vibha, D. (2009). Reversible dementias.. PubMed.
773. Trujillo, K. A. (2012). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence A Review of the Research, A Cellular Model, and Implications for the Treatment of Pain and Addiction.
774. Tsai, L., & Liou, H. (2015). Current Treatment for Generalized Convulsive Status Epilepticus in Adults.. PubMed.
775. Tseng, Y., Wellman, S. E., & Ho, I. (2020). Sedative-Hypnotics: Addiction and Current Research Status. Journal of Food and Drug Analysis. https://doi.org/10.38212/2224-6614.3068
776. Tugendhaft, P. (2004). [The follow-up of antiepileptic drugs].. PubMed.
777. Turner, W. J. (2018). Mental Health and Homicide in Medieval English Trials. Open Library of Humanities. https://doi.org/10.16995/olh.295
778. Ueda, S., Sakayori, T., Omori, A., Fukuta, H., Kobayashi, T., Ishizaka, K., Saijo, T., & Okubo, Y. (2016). Neuroleptic-induced deficit syndrome in bipolar disorder with psychosis. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s99577
779. Ungar, A. K., Konova, A. B., Patel, A. N., Goldstein, R. Z., & Hurd, Y. L. (2016). Substance Use and Addictive Disorders. https://doi.org/10.1002/9781118654231.ch16
780. Uyar, R., Türk, C. Ç., Işik, N., Kalelioğlu, M., Onat, F., & Özek, M. M. (2014). The acute and delayed effects of vagal nerve stimulation in absence epilepsy model on wagrij. Turkish Neurosurgery. https://doi.org/10.5137/1019-5149.jtn.12947-14.0
781. Vally, M., & Kathrada, F. (2019). Understanding Alzheimer disease. South African Family Practice. https://doi.org/10.4102/safp.v61i2.4999
782. Valério, F., Whitehouse, D., Menon, D., & Newcombe, V. (2020). The neurological sequelae of pandemics and epidemics. Journal of Neurology. https://doi.org/10.1007/s00415-020-10261-3
783. Vanderver, A., Tonduti, D., Schiffmann, R., Schmidt, J., & Knaap, M. S. V. D. (1993). Leukodystrophy Overview – ARCHIVED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
784. Vargha‐Khadem, F. (2001). Generalized Versus Selective Cognitive Impairments Resulting from Brain Damage Sustained in Childhood. Epilepsia. https://doi.org/10.1046/j.1528-1157.2001.00513.x
785. Vasilyeva, Y. B. (2019). Clinical Features of Traumatic Brain Injury in Various Kinds of Brain Damage. Russian Sklifosovsky Journal Emergency Medical Care. https://doi.org/10.23934/2223-9022-2019-8-3-295-301
786. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
787. Venkataraman, A., Turton, S., & Lingford‐Hughes, A. (2020). Drug use and associated neuropsychiatric conditions. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198757139.003.0028
788. Vernino, S., & Vincent, A. (2013). Autoimmune and paraneoplastic autonomic neuropathies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198566342.003.0054
789. Vgontzas, A. N., Fernández‐Mendoza, J., Bixler, E. O., Singareddy, R., Shaffer, M. L., Calhoun, S. L., Liao, D., Basta, M., & Chrousos, G. P. (2011). Persistent Insomnia: the Role of Objective Short Sleep Duration and Mental Health. SLEEP. https://doi.org/10.5665/sleep.1586
790. Vicente, J. F. M. (2014). Estado epiléptico refractario en el entorno de la terapia intensiva. Medicina Crítica.
791. Vidal, J. P. (2019). Tratar la depresión en el anciano, ¿hasta cuándo?. Informaciones psiquiátricas: Publicación científica de los Centros de la Congregación de Hermanas Hospitalarias del Sagrado Corazón de Jesús.
792. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
793. Virmani, A., Ali, S. F., & Binienda, Z. (2010). Neuroprotective strategies in drug abuse‐evoked encephalopathy. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.05171.x
794. Vn, S., & Am, G. (1994). [The neurology of terminal states].. PubMed.
795. Volpe, B. T. (1997). Delayed Neuronal Degeneration Results from Endogenous Glutamate Excess. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1997.tb48390.x
796. Volpe‐Gillot, L. (2007). Troubles cognitifs, démence et épilepsie. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2007.0097
797. Vukmir, R., Valeriano, J., & Oblack, A. (2023). Brain Death. Cambridge University Press eBooks. https://doi.org/10.1017/9781316338513.027
798. Vulser, H., & Lebeau, G. (2019). Post-Traumatic Stress Disorder Following Intraoperative Awareness. Neuromethods. https://doi.org/10.1007/978-1-4939-9891-3_5
799. Vučković, S., Till, E., Lisulov, R., & Nedić, A. (1989). [The neuroleptic malignant syndrome].. PubMed.
800. Wang, M. Y., & Sadun, A. A. (2013). Drug-Related Mitochondrial Optic Neuropathies. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/wno.0b013e3182901969
801. Wang, R., & Bi, H. (2021). Auditory temporal processing deficits in developmental dyslexia. Advances in Psychological Science. https://doi.org/10.3724/sp.j.1042.2021.01231
802. Wasserman, D., Bassetti, C. L., & Rosenzweig, I. (2020). Narcolepsy with resolution of cataplexy and persisting orexin deficiency. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.8572
803. Weaver, M. F., Heads, A. M., & Faillace, L. A. (2024). Mood Disorders and Comorbid Substance Use Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108973922.013
804. Weber, P., Vepřeková, B., & Kadaňka, Z. (2009). Psychiatrická problematika v intenzivní medicíně vyššího věku.
805. Werf-Eldering, M. J. V. D., Schouws, S., Arts, B., & Jabben, N. (2012). [Cognitive dysfunction in bipolar disorder: determinants and functional outcome].. PubMed.
806. Wiederhold, B. K., Garmon, E. H., & O'Rourke, M. C. (2019). Nerve Block Anesthesia.
807. Wierenga, C. E., & Bondi, M. W. (2011). Dementia and Alzheimer's Disease: What We Know Now. Generations.
808. Wijdicks, E. F. M. (2014). Neurologic Disorders in Film. CRC Press eBooks. https://doi.org/10.1201/b17682-3
809. Wijdicks, E. F. M. (2025). Neurology of Overdose. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197544976.003.0052
810. Wijdicks, E. F. M. (2025). “Blacked Out and Slumped Down”. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197544976.003.0007
811. Wijdicks, E. F. M., & Clark, S. L. (2018). Drugs Used in Neurorehabilitation. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190684747.003.0020
812. Wilkins, C. H. (2008). Late life depression with cognitive impairment: Evaluation and treatment. Clinical Interventions in Aging. https://doi.org/10.2147/cia.s3154
813. Williams, M. D. (2018). Dynamique de l’excitabilité corticale dans l’épilepsie-absence et intégration sensorielle.
814. Willroth, E. C., James, B. D., Graham, E. K., Kapasi, A., Bennett, D. A., & Mroczek, D. K. (2022). Well-being and Cognitive Resilience to Dementia-related Neuropathology. https://doi.org/10.31234/osf.io/sbh85
815. Wilson, J., & Wiedmann, K. D. (2018). Neuropsychological Assessment in Alcohol, Drug Abuse and Toxic Conditions. Routledge eBooks. https://doi.org/10.4324/9780429490316-15
816. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
817. Windebank, A. J., & Grisold, W. (2008). Chemotherapy‐induced neuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/j.1529-8027.2008.00156.x
818. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
819. Wit, L. D., & Kessels, R. (2024). Niet-farmacologische interventies bij lichte cognitieve stoornissen (MCI) en dementie. Tijdschrift voor Neuropsychologie. https://doi.org/10.5553/np/187113912024019003003
820. Wolf, M. E. (2002). Addiction and Glutamate-Dependent Plasticity. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_8
821. Wright, S. L. (2020). Benzodiazepine Withdrawal. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197517277.003.0008
822. Xu, S.-Y., Li, Z.-X., Wu, X., Li, L., & Li, C. (2020). Frequency and Pathophysiology of Post-Seizure Todd’s Paralysis. Medical Science Monitor. https://doi.org/10.12659/msm.920751
823. Yadav, L., Khosla, P., Taneja, V., & Dessai, R. (2023). Primary adrenal insufficiency presenting with neuropsychiatric illness. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20232447
824. Yan, H., Cao, X., Gao, T., & Zhu, X. (2011). Promoting Adult Hippocampal Neurogenesis: A Novel Strategy for Antidepressant Drug Screening. Current Medicinal Chemistry. https://doi.org/10.2174/092986711797200471
825. Yan, R. M., Cardonne, M. M., Reyes, E. J. M., & Leyva, A. G. (2022). Herramienta para la obtención de Patrones de Conectividad Cerebral en Pacientes con Deterioro Cognitivo. Orange Journal. https://doi.org/10.46502/issn.2710-995x/2021.6.04
826. Yang, T., Guo, R., Ofengeim, D., Hwang, J.-Y., Zukin, R. S., Chen, J., & Zhang, F. (2021). Molecular and Cellular Mechanisms of Ischemia-Induced Neuronal Death. Stroke. https://doi.org/10.1016/b978-0-323-69424-7.00005-3
827. Yang, Y., Zhang, J., Han, F., & Xiao, F. (2022). Not Only Excessive Daytime Sleepiness but Also Depression Symptoms, Chronological Age and Onset-Age Were Associated with Impulsivity in Narcolepsy Type 1 Patients. Nature and Science of Sleep. https://doi.org/10.2147/nss.s377372
828. Yirmiya, D., Rimmerman, N., & Reshef, R. (2015). Depression as a Microglial.
829. Young, M. J., Edlow, B. L., & Bodien, Y. G. (2024). Covert consciousness. Neurorehabilitation. https://doi.org/10.3233/nre-230123
830. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
831. Yu, S., Leng, Y., Wang, Y., & Guoqing, Z. (2022). A Review of the Biological Mechanisms of Dexmedetomidine for Postoperative Neurocognitive Disorders. Medical Science Monitor. https://doi.org/10.12659/msm.937862
832. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
833. Yui, K. (2015). EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders). Current Neuropharmacology. https://doi.org/10.2174/1570159x1306151126144423
834. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
835. Yönt, Y. D. D. H., & Korhan, A. G. D. E. A. (2010). İnmeli Hastalarda İhmal Edilen Bir Sorun: Patolojik Gülme ve Ağlama. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi.
836. Zawilska, J. B., Santorek‐Strumiłło, E., & Kuna, P. (2010). [Nighttime eating disorders--clinical symptoms and treatment].. PubMed.
837. Zdybel, M., Rdzanek, B. J., & Skrzypek, W. (2025). OBSESSIVE COMPULSIVE DISORDER - A REVIEW OF TREATMENT METHODS. International Journal of Innovative Technologies in Social Science. https://doi.org/10.31435/ijitss.3(47).2025.3714
838. Zhang, J., Williams, J. P., Zhao, Q.-N., Liu, H., Shi, W., Wang, Y., Fang, Q.-W., & An, J. (2021). Multimodal sleep, an innovation for treating chronic insomnia: case report and literature review. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.9310
839. Zúñiga, R. L. (2017). Delirium y la presencia de respuesta inflamatoria sistémica, descontrol glucémico e hipoxia en pacientes mayores de 65 años en el servicio de urgencias médicas del Hospital General de Pachuca..
840. Özdemir, İ., Kuru, E., Şafak, Y., & Tulacı, R. G. (2018). A Neuroleptic Malignant Syndrome Without Rigidity. Psychiatry Investigation. https://doi.org/10.30773/pi.2017.06.05
841. Česká, K., Horák, O., Ošlejšková, H., & Aulická, Š. (2018). Nově vzniklý refrakterní status epilepticus a syndromy z blízkého spektra (NORSE/FIRES).
842. Świaczny, S. (2011). Nerwica natręctw a kanoniczny konsens małżeński. Annales Canonici. https://doi.org/10.15633/ac.0714
843. Šajfar, L. (2015). Demencija i uloga medicinske sestre.
844. Šumarac-Dumanović, M., Micić, D., Macut, Đ. P., Kendereški, A., Zorić, S., Cvijović, G., & Pejković, D. (2002). Hipoglikemijski sindromi - dijagnostički i terapijski pristup i prikaz dva slučaja. ABC - časopis urgentne medicine.
845. Żarowski, M., Steinborn, B., & Kothare, S. V. (2014). Narcolepsy in children. Child Neurology.
846. Žaja, O., Darija, Č., Lesar, T., & Bradovski, Z. (2012). Approach to the treatment of malnutrition somatic consequences in children with anorexia nervosa.